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ABSTRACT

Draper, Christiana S. I. Ph.D., Biomedical Sciences Ph.D. Program, Wright State
University, 2021. ALS-induced Excitability Changes in Individual Motorneurons and the
Spinal Motorneuron Network in SOD1-G93A Mice at Symptom Onset.

Amyotrophic lateral sclerosis (ALS) is the most common motorneuron (MN)
disease in adulthood. ALS is hallmarked by the progressive loss of MNs in the brain,
brainstem, and spinal cord. Many hypotheses to explain the pathogenesis of ALS have
been explored, but the exact mechanisms underlying the development of this disease
remain unknown. However, abnormalities in MN excitability and glutamate
excitotoxicity are the most widely studied. For decades, researchers have examined MN
excitability in ALS, but the current literature is inconsistent, showing evidence of
hyperexcitability, hypoexcitability, or no change in excitability of MNs in ALS. Many of
these studies also focus solely on the excitability of individual MNs, rather than the
spinal MN network, whose output collectively drives muscle activity. Using
electrophysiology intracellular and ventral root recordings in SOD1-G93AHigh-Copy (SOD)
mice, the standard rodent model of ALS, at symptom onset, we demonstrate evidence of
both hypo- and hyperexcitability in ALS, whereby disease mechanisms change MN
excitability in one direction and compensatory mechanisms alter MN excitability in the
opposite direction. Additionally, we show evidence of a novel mechanism contributing to
the development of motor dysfunction in ALS at symptom onset, impaired sensorimotor
iv

integration.
We also studied the effects of a novel treatment for ALS on MN excitability. In
recent years, small-conductance calcium-activated potassium (SK) channels have been
implicated in the pathogenesis of ALS. In MNs, these channels mediate the
afterhyperpolarization (AHP) and synaptic transmission and plasticity and subsequently
regulate MN excitability at the individual and network levels. In SOD mice, these
channels are significantly reduced throughout disease progression and early treatment
with an SK channel activator, CyPPA, restores these deficits. Early treatment with
CyPPA also prolongs the survival and motor function of SOD mice. Our results
demonstrate that the long-term therapeutic benefits of CyPPA in SOD mice are not due to
alterations in MN excitability. SK channels are also implicated in neuroinflammation and
microglia activation, mitochondrial dysfunction, and many other putative mechanisms
related to ALS. Thus, deficits in one of these alternative molecular pathways is likely
restored with early CyPPA treatment in SOD mice.
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Chapter I: Purpose and Specific Aims
Purpose
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease
that predominantly affects the middle-aged population. ALS is characterized by the loss
of both upper and lower motorneurons (MNs), which leads to paralysis and ultimately
death, within 3-5 years following diagnosis. To date, the pathogenesis underlying ALS is
largely unknown, but abnormalities in MN excitability remain the most tightly linked to
disease mechanisms. For decades, researchers have investigated the excitability state of
MNs in ALS, but the results are widely inconsistent and vary depending on the study. In
addition, most of these researchers investigated changes in individual MNs but very few
examined the effects of ALS on the spinal MN network. This project addressed these
gaps in the literature and investigated the long-term effects of a novel treatment for ALS,
CyPPA1.
In the first specific aim, we examined the excitability state of individual MNs and
the spinal MN network at symptom onset in SOD1-G93AHigh-Copy (SOD) mice, which are
the standard rodent model of ALS. Also, symptom onset is the critical time-point in
diseases where despite maximum compensation, disease alterations prevail, and the first
external evidence of a problem emerges (i.e., symptoms).
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Next, we examined the long-term effects of a small-conductance calcium-activated
potassium (SK) channel activator, CyPPA, in SOD mice. Under normal physiological
conditions, SK channels regulate MN excitability, but previous investigations in our lab
revealed SK channel deficits in SOD mice (Dukkipati, 2016). Early treatment with CyPPA
improved these deficits and prolonged survival and motor function in these animals
(Dancy, 2017; Murphy, 2020). However, the long-term effects of CyPPA on the
excitability of SOD MNs at the individual and network levels was not investigated. Hence,
this project furthers our understanding of the disease versus compensatory mechanisms
associated with ALS, the inconsistencies concerning MN excitability in ALS within the
literature, and the mechanisms underlying the therapeutic benefits of CyPPA in ALS.

2

Specific Aims
Specific Aim 1: Investigate ALS-induced excitability changes in individual MNs and
the spinal MN network in SOD mice at symptom onset.
Hypothesis: Disease and compensatory mechanisms in ALS cause opposing changes in
MN excitability. Thus, at symptom onset, individual SOD MNs exhibit both hypo- and
hyperexcitable changes in intrinsic electrical properties. Additionally, because MN
excitability is also influenced by synaptic inputs, alterations in sensory and descending
motor inputs in the spinal MN network of SOD mice at symptom onset contribute to
changes in MN excitability.
Aim 1A: Examine the effects of ALS on the excitability of individual MNs in SOD mice
at symptom onset.
Aim 1B: Examine the effects of ALS on the excitability of the spinal MN network in
SOD mice at symptom onset.
Rationale: Presently, the literature examining MN excitability in ALS is widely
inconsistent, showing evidence of hyperexcitability, hypoexcitability, or no change in the
excitability of MNs depending on the study. Many of these studies also focus on
individual MNs rather than the spinal MN network, whose output2 collectively drives
muscle activity. Using intracellular and ventral root recordings, we studied the effects of
ALS on the excitability of individual MNs and the spinal MN network in SOD mice at
symptom onset. Altogether, these data explain the controversial state of ALS literature
surrounding MN excitability and identify a novel mechanism contributing to the
development of motor dysfunction in ALS.

2
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Specific Aim 2: Determine the long-term effects of early treatment of SOD mice
with CyPPA on the excitability of individual MNs and the spinal MN network.
Hypothesis: Early treatment of SOD mice with CyPPA increases the conductance of SK
channels (GSK density) and the amplitude of the afterhyperpolarization (AHP) in
individual SOD MNs at symptom onset. Additionally, because SK channels influence
synaptic transmission and plasticity (Faber et al., 2005; Nanou et al., 2013), early
treatment with CyPPA alters one or both of these synaptic properties in the spinal MN
network of SOD mice at symptom onset.
Aim 2A: Examine the long-term effects of early treatment of SOD mice with CyPPA on
the excitability of individual MNs.
Aim 2B: Investigate the long-term effects of early treatment of SOD mice with CyPPA
on the excitability of the spinal MN network.
Rationale: In ALS, large, fast (F)-type MNs are more vulnerable to degeneration than
small, slow (S)-type MNs (Hegedus et al., 2007; Hegedus et al., 2008; Pun et al., 2006;
Saxena et al., 2013). Previous data has also shown that F-type MNs have an intrinsically
lower expression of SK channels than S-type MNs (Deardorff et al., 2013). SK channels
mediate the AHP (Meech, 1978; Ransom et al., 1975; Wikström & El Manira, 1998) and
subsequently influence MN discharge or firing rates (Manuel et al., 2006; Viana et al.,
1993). More recently, our lab found SK channel downregulation throughout disease
progression in SOD mice using immunohistochemistry (Dukkipati, 2016) and established
the therapeutic potential of an SK channel activator, CyPPA, in ALS. CyPPA restores the
somatic clustering profile of SK channels, improves motor function, and prolongs the
survival of SOD mice (Dancy, 2017; Murphy, 2020). However, SK channels are not only

4

found on the soma of MNs but exist on the dendrites to modulate synaptic inputs (Nanou
et al., 2013) and influence the spinal MN network. Using intracellular and ventral root
recordings from adult SOD mice treated with CyPPA during the neonatal period, we
investigated the long-term effects of CyPPA on the excitability of individual MNs and
the spinal MN network in SOD mice. Together, these data further elucidate the
therapeutic potential of CyPPA in ALS.

5

Chapter II: Background
Amyotrophic lateral sclerosis (ALS)
ALS is the most common motorneuron (MN) disease with an estimated
prevalence of 5.2 cases per 100,000 people in the United States (Mehta et al., 2018). ALS
is hallmarked by the progressive degeneration of MNs in the brain, brainstem, and spinal
cord, resulting in the dysfunction of somatic muscles in the body (Rowland & Shneider,
2001; Talbot, 2009; Taylor et al., 2016). The onset of symptoms is typically between the
ages of 50 and 65 and males carry a higher risk for developing the disease (Ingre et al.,
2015; Kurtzke, 1982; Logroscino et al., 2010; PARALS, 2001; Zarei et al., 2015)
Patients with ALS initially present with muscle atrophy and weakness that
progresses to paralysis. Within a short period, the disease spreads to the respiratory
muscles impairing breathing and eventually causing death. Currently, there are no valid
diagnostic biomarkers for ALS, which requires physicians to identify ALS solely based
on the signs, symptoms, and medical history of patients. However, many of the initial
symptoms associated with ALS are nonspecific and may resemble features of other
neuromuscular diseases causing a delay in diagnosis (Longinetti & Fang, 2019). This
delay is further extended by the required evidence of the progressive spread of symptoms
in ALS. Altogether, the mean time from the onset of symptoms to diagnosis is
approximately 12 months (Mitchell et al., 2010; Paganoni et al., 2014) and median
survival from symptom onset ranges from 2-5 years, depending on the clinical and
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pathological syndrome (Chancellor et al., 1993; Logroscino et al., 2008; Norris et al.,
1993).
While the majority of ALS cases are sporadic (sALS), about 10 percent of
patients have a familial (fALS) form of the disease due to mutations most commonly
associated with the following: Cu/Zn superoxide dismutase 1 (SOD1), TAR-DNA
binding protein 43 (TDP-43), fused in sarcoma (FUS), and chromosome 9 open reading
frame 72 (C9ORF72) (Boylan, 2015; Haverkamp et al., 1995). The SOD1 gene was the
first to be associated with ALS and mutations in this gene account for approximately 15
percent of fALS cases but fewer than 2 percent of sALS cases (Zou et al., 2017). To date,
over 185 disease-associated variations in SOD1 have been identified and phenotype,
disease duration, and severity differ depending on the variants involved (Yamashita &
Ando, 2015). For instance, patients with a glycine-to-arginine mutation at amino acid 85
(G85R) typically exhibit rapid disease progression and shorter survival times (Yamashita
& Ando, 2015).
TDP-43 is a DNA/RNA binding protein encoded by the TARDBP gene that forms
ubiquitinated protein aggregates in the brain and spinal cord of most ALS patients (Arai
et al., 2006; Mejzini et al., 2019; Neumann et al., 2006; Schipper et al., 2016). Presently,
at least 48 variants in TARDBP have been identified in ALS (Lattante et al., 2013). In
2009, variants in a gene encoding another RNA binding protein, FUS, were discovered in
a subset of ALS patients (Kwiatkowski et al., 2009; Vance et al., 2009). These variants
are often associated with early onset and juvenile ALS rather than the typical late
adulthood disease (Gromicho et al., 2017; Hübers et al., 2015; Zou et al., 2013). A few
years later, a hexanucleotide repeat expansion (GGGGCC) in the noncoding region of the
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C9ORF72 gene was discovered as the most common genetic cause of ALS in the
European population (DeJesus-Hernandez et al., 2011; Renton et al., 2011). This genetic
variant accounts for approximately 34 percent of fALS cases and 5 percent of sALS cases
in the European population (Zou et al., 2017). To date, researchers have conducted
extensive research examining the genetic basis of ALS and have identified more than 20
genes associated with the familial inheritance of this disease (Boylan, 2015; Yamashita &
Ando, 2015). Yet, despite this compilation of knowledge, there are only a few current
treatments for ALS.
Current ALS treatments
Current treatment options for ALS patients include multidisciplinary symptom
management, which involves nutrition, communication, and respiratory support (Hogden
et al., 2017; Mejzini et al., 2019) and two Food and Drug Administration (FDA)
approved medications. In 1995, the FDA approved the first drug to treat ALS, Riluzole
(Jaiswal, 2019; Petrov et al., 2017). Riluzole is a known glutamate antagonist that was
originally used as an anticonvulsant, but its mechanism of action (MOA) in ALS is much
more complex (Bellingham, 2011). Previous research shows that Riluzole has limited
effects on glutamate receptors in ALS and that its pharmacological benefits are likely
related to the inactivation of voltage-dependent sodium channels and interference with
intracellular events that follow neurotransmitter binding at excitatory amino acid
receptors (Jaiswal, 2019). Riluzole is only slightly effective in some ALS patients,
prolonging their lifespan for up to 2-3 months but offering little to no improvement in
their quality of life (Bensimon et al., 1994; Lacomblez et al., 1996; Miller et al., 2012).
Since 1995, researchers have investigated over 60 other molecules as potential treatments
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for ALS (DeLoach et al., 2015; Mitsumoto et al., 2014). Many of these molecules delay
progression in preclinical animal models of ALS but fail to show efficacy in human
clinical trials (Jaiswal, 2019; Petrov et al., 2017).
In 2017, the FDA approved Edaravone to treat ALS (Rothstein, 2017). Edaravone
is an anti-oxidative compound that likely reduces oxidative injury to MNs and glial cells
at risk for degeneration in ALS (Mejzini et al., 2019), but its exact MOA is still unknown
(Jaiswal, 2019). Patients treated with Edaravone for 6 months show a 33 percent
reduction in the rate of decline of physical function when compared to patients receiving
a placebo (Bhandari et al., 2018; Jaiswal, 2019; Sawada, 2017). Collectively, the current
literature on Riluzole and Edaravone treatment in ALS patients shows modest positive
outcomes with no evidence of halting the disease or improving quality of life (Bhandari
et al., 2018; Jaiswal, 2019; Miller et al., 2012). The limited and ineffectual treatment
options available for ALS patients are a consequence of the disease’s unclear etiology.
Glutamate excitotoxicity theory in ALS
Currently, there are many theories regarding the pathogenesis of ALS including
oxidative stress, mitochondrial dysregulation, deficits in neurofilament and axonal
transport, and glutamate excitotoxity (Hirano et al., 1984; Mejzini et al., 2019; Rouleau et
al., 1996; Shibata et al., 2001). Glutamate excitotoxicity is one of the most longstanding
and well-studied hypotheses associated with ALS. It was first introduced in the 1990s
following the discovery of significantly elevated N-acetyl-aspartyl glutamate and its
metabolite N-acetyl aspartate in the cerebrospinal fluid (CSF) of patients with ALS
(Rothstein et al., 1990). These findings led to the development of the excitotoxicity
theory which attributes the pathophysiology of ALS to abnormal chronic exposure of
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neurons to excitotoxic substances, such as glutamate or glutamate analogs. This excess
glutamate activity causes an increase in intracellular calcium via glutamate receptors
during synaptic transmission and voltage-gated calcium channels following an action
potential (AP). Thereafter, the surplus calcium entry induces neuronal cell death by
activation of enzymes, such as lipases and phospholipases, initiation of mitochondrial
dysfunction resulting in the production of oxidative reactive species, and/or facilitation of
numerous other putative mechanisms related to ALS (i.e., non-cell autonomous astrocyte
involvement) (Geevasinga et al., 2016; Spalloni et al., 2013; Van Den Bosch et al., 2006).
Correspondingly, the only FDA approved drug used to treat ALS prior to 2017,
Riluzole, has anti-excitotoxic properties (Bensimon et al., 1994; Lacomblez et al., 1996).
In addition, MNs, the cells that undergo degeneration in ALS, are extremely sensitive to
excessive stimulation of glutamate receptors due to their normal intrinsic properties
related to calcium. MNs have a decreased capacity to buffer or stabilize excess
intracellular calcium due to their low expression of calcium buffering proteins (Van Den
Bosch et al., 2006). Previous studies also demonstrate differences within MN
subpopulations where the most vulnerable MNs to ALS in the spinal cord lack calcium
binding proteins, such as parvalbumin and calbindin D28K, compared to the less
vulnerable MNs in the oculomotor, trochlear, abducens, and Onuf nuclei (Alexianu et al.,
1994; Celio, 1990; Ince et al., 1993). MNs also possess a higher portion of calcium
permeable AMPA3 receptors and stimulation of these receptors leads to selective MN
death (Carriedo et al., 1996; Van Den Bosch et al., 2000). Under normal conditions, these
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features allow MNs to carry out their physiological function, but under pathological
conditions they may aid disease mechanisms.
Altogether, these data provide evidence to support the glutamate excitotoxicity
hypothesis in ALS. However, if this theory holds true, MNs in ALS would be
hyperexcitable. However, much of the current literature examining MN excitability in
ALS is inconsistent.
MN excitability in ALS
MN excitability is determined by interacting cellular properties or “subcomponents” such as cell size, passive membrane properties, voltage-gated sodium and
calcium persistent inward currents (NaPIC and CaPIC), and synaptic input. To date,
researchers have extensively examined MN excitability in ALS using spinal cord tissue
from SOD1-G93AHigh-Copy (SOD) mice. SOD mice overexpress the SOD1 gene with a
glycine-to-alanine mutation at amino acid 93. These mice were the first true ALS model
to emerge (Gurney et al., 1994) and are still the most widely used. SOD mice develop a
progressive paralysis beginning in the hindlimbs at postnatal day (P) 90 and reach end
stage at roughly P135.
MNs from SOD embryos exhibit hyperexcitability due to upregulation of the
NaPIC (Kuo et al., 2005; Pieri et al., 2003) and reduced dendritic elongation (Martin et
al., 2013). Neonatal SOD MNs also display a robust upregulation of NaPIC and CaPIC
(Quinlan et al., 2011; van Zundert et al., 2008). However, a substantial increase in input
conductance counteracts this increase in PIC and the overall excitability of neonatal SOD
MNs remain unchanged (Quinlan et al., 2011). These results are further supported by a
study that examined the excitability of MN subtypes in neonatal SOD mice.
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MN subtypes are differentially vulnerable to ALS whereby the large MNs that
innervate the fast-contracting fibers (F-type MNs) are more vulnerable to the disease and
degenerate first compared to the small MNs that innervate the slow-contracting fibers (Stype MNs) (Hegedus et al., 2008; Pun et al., 2006). Remarkably, S-type neonatal SOD
MNs exhibit hyperexcitability characterized by a lower rheobase 4 and hyperpolarized
spiking threshold, while F-type neonatal SOD MNs do not (Leroy et al., 2014). Together,
these findings suggest that early intrinsic hyperexcitability does not contribute to the
degeneration of MNs in ALS.
Conversely, some SOD adult MNs lose their ability to fire repetitively, exhibiting
hypoexcitability before symptom onset (Delestrée et al., 2014; Martínez-Silva et al.,
2018). Studies of specific proteins inside these MNs confirmed the hypoexcitable cells
were further along in the disease process and thus represent F-type or disease vulnerable
MNs (Martínez-Silva et al., 2018) These data provide evidence of hypo- rather than
hyperexcitability as the key player in ALS disease processes. However, some researchers
have recently attributed this hypoexcitability to an injury response to microelectrode
impalement (Jensen et al., 2020). In fact, they found MNs from adult pre-symptomatic
(P69-P75) and symptomatic (P107-P116) SOD mice to be intrinsically more responsive.
These cells exhibited a lower rheobase and higher input resistance and gain, but lacked
deficits in repetitive firing when electrodes had proper time to seal (Jensen et al., 2020).
To address the inconsistencies discussed above and further understand how MN
excitability changes in ALS, Huh and colleagues (2021) conducted a time course study
using SOD mice. This study examined the electrical alterations in MNs from SOD mice
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The minimal amount of current needed to produce an action potential
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in three different age groups, P30-P60 (young adult), P60-P90 (pre-symptomatic), and
P90-P120 (symptomatic). In these analyses, young adult SOD MNs exhibited abnormally
large PICs coupled with an increased input conductance, leaving their net excitability
unchanged. Later, in pre-symptomatic SOD MNs, these properties returned to normal.
Then finally, in symptomatic SOD MNs, input conductance and recruitment current were
reduced. While this study provided the first evidence of fluctuations in MN excitability
parameters throughout ALS disease progression, it failed to explain the current state of
the literature (Huh et al., 2021). Similar conflicting results have also been found in ALS
patient-derived induced pluripotent stem cells (iPSCs) (Devlin et al., 2015; Naujock et
al., 2016).
In total, the previous literature examining MN excitability in ALS is widely
inconsistent. This variability could be attributed to experimental design or error and/or
disease and compensatory mechanisms having opposing effects on MN excitability. In
order to address these gaps in knowledge and explain the current literature, additional
research examining MN excitability in ALS is needed.
The spinal MN network in ALS
The firing rate of a MN is influenced by its intrinsic electrical properties and its
synaptic properties. Therefore, excitotoxicity in ALS could emerge from changes in the
intrinsic electrical properties of MNs and/or from an increase or decrease in the activity
of neurons that synapse onto MNs. Previous literature has provided key evidence
supporting the involvement of synaptic mechanisms in ALS. Both ALS patients and
rodent models exhibit loss of glutamate transporters in astrocytes, which may enhance
extracellular glutamate (Bendotti et al., 2001; Bruijn et al., 1997; Rothstein et al., 1992;
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Rothstein et al., 1995), and inefficient RNA editing of GluR2 mRNA leading to increased
calcium permeability of AMPA receptors (Kwak et al., 2010; Tortarolo et al., 2006). In
addition, hypoglossal and cortical MNs show an increase in synaptic transmission in
SOD mice (Saba et al., 2015; van Zundert et al., 2008). Some data also suggests the
involvement of a disinhibitory synaptic mechanism due to a breakdown in glycinergic
transmission (Chang & Martin, 2011; McGown et al., 2013) and synapses between MNs
and Renshaw cells (interneurons which receive synaptic inputs from MNs and inhibit
those same MNs upon activation) (Wootz et al., 2013).
Even still, only a few studies have examined these changes at the system or spinal
MN network level, which encompasses the summation of the spiking activities of MNs,
interneurons, and their synapses in the spinal cord and thus represents the functional
motor output. In the spinal cord, three inputs regulate the firing pattern of MNs,
descending motor commands from supraspinal structures, sensory inputs from the
periphery, and local interneuronal inputs within the spinal cord (Carp & Wolpaw, 2010).
Integration of these inputs allow an individual to generate stable and appropriate motor
output in response to a given motor task (Kim et al., 2017; Mahrous et al., 2019; Nielsen,
2004; Rossignol et al., 2006). More specifically, sensory inputs influence the prevention,
allowance, and selection of motor patterns and play a pivotal role in responding to
perturbations or obstacles during locomotion, while descending motor inputs activate the
spinal locomotor networks to initiate locomotion (Rossignol et al., 2006). These two
synaptic pathways converge onto common spinal interneurons (Nielsen, 2004) and the
spinal MN pool (Brown & Fyffe, 1981; Eccles, 1946; Liang et al., 2014; Riddle et al.,
2009; Witham et al., 2016) to permit the performance of skilled motor tasks and shape
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locomotor output. The integration of this synaptic information in MNs is influenced by
several factors (Heckman et al., 2004; Heckman & Lee, 1999; Magee, 2000; Spruston,
2008) including the pattern of synaptic plasticity, which plays an important role in
determining motor input-output function under normal and disease conditions (Wolpaw
& Tennissen, 2001).
Synaptic plasticity refers to the activity-dependent modification of the strength or
efficacy of synaptic transmission at preexisting synapses (Citri & Malenka, 2008). With
repetitive activation, synaptic transmission can either be enhanced or depressed and these
changes can last for milliseconds (i.e. short-term plasticity) or days (i.e. long-term
plasticity) (Citri & Malenka, 2008). Short-term modifications are common to all neurons
in the nervous system (Regehr, 2012; Zucker & Regehr, 2002). Thus, with successive or
repetitive stimuli, some synaptic inputs to MNs become progressively smaller or undergo
synaptic depression, while others become progressively larger or undergo synaptic
facilitation (Jiang et al., 2015; Mahrous et al., 2019). Recent studies demonstrated that
sensory and descending motor inputs in the spinal cord exhibit variable forms of system
short-term plasticity (Jiang et al., 2015; Mahrous et al., 2019).
Sensory inputs largely include a prominent low threshold monosynaptic
component via activation of muscle spindle Ia afferents and exhibit system short-term
depression (sSTD) following successive stimulation. However, descending motor inputs
are composed of both monosynaptic and polysynaptic connections to MNs and exhibit
frequency dependent bimodal plasticity, sSTD at low-stimulation frequencies but system
short-term facilitation (sSTF) at high-stimulation frequencies (Jiang et al., 2015). The
primary cause for these differences in these two synaptic pathways is due to the
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activation of excitatory inputs from monosynaptic sources in the sensory system
compared to local interneuronal networks in the descending system (Jiang et al., 2015).
These differences also correspond to the functional role of each of these pathways. For
example, normal locomotion evokes a strong increase in proprioceptive sensory inputs
from the periphery and other sensory inputs to relay information about the position of the
limbs and body relative to the surroundings. A reduction in this inflow may be necessary
in order to prevent interference with movements (Jacobs & Fornal, 1993; Stein &
Capaday, 1988) and thus sSTD in sensory inputs may facilitate this level of control.
Previous ALS research examining sensory inputs in SOD mice show conflicting
results. One study found a decrease in the amplitude of sensory inputs throughout disease
progression (P50-P130) and concluded these inputs do not contribute to hyperexcitability
(Jiang et al., 2009), while another study showed sensory inputs in pre-symptomatic (P50P90) SOD mice exhibit less sSTD resulting in enhanced repetitive firing and
hyperexcitability (Jiang et al., 2017). These contradictory results, along with no studies
that examine descending motor inputs or their integration with sensory inputs,
demonstrate the need for additional research to determine the effects of ALS on the spinal
MN network.
Neurodegenerative Diseases: Disease versus Compensation
ALS, like other neurodegenerative diseases, has three phases (Talbot, 2014).
During normal development and progression, different genetic variations and
environmental factors influence an individual’s later susceptibility to degeneration, but
there is no evidence of dysfunction during this time. This is known as the initial or
susceptibility phase. During the pre-clinical or pre-symptomatic phase, susceptible
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individuals have abnormal neuronal function, but do not display clinical symptoms due to
the system’s intrinsic reserve capacity or other compensatory mechanisms in operation.
When the reserve capacity or compensatory mechanisms are exceeded by disease
mechanisms, individuals develop symptoms (i.e., the first external evidence of a
problem) and the clinical phase begins.
Evidence of these phases are supported by the numerous genetic variants and
environmental factors which increase the risk of ALS (Ingre et al., 2015). In addition,
before symptom onset, ALS patients and rodent models exhibit neuronal cell loss but no
alterations in motor function or behavior (Aggarwal & Nicholson, 2002; Hegedus et al.,
2007). During this time, numerous compensatory mechanisms maintain the neural drive
to the muscles and thwart clinical manifestation of the disease. Conversely, at symptom
onset, despite maximum compensation, disease processes predominate impairing the
neural drive which sparks rapid motor decline.
Throughout disease progression, dynamic interactions between disease and
compensatory mechanisms cause unstable fluctuations or alterations in MN cellular
properties (Huh et al., 2021; Mitchell & Lee, 2012). The conflicting results in studies
investigating the excitability of individual MNs and the spinal MN network in ALS may
be due to these oscillations or variations throughout disease progression. Thus, depending
on the time of the study or the state of the regulatory mechanisms compared to the
disease mechanisms, researchers may find different changes in the same cellular
properties. In Chapter IV of the current study, we investigated the excitability state of
individual MNs and the spinal MN network in SOD mice at symptom onset. Presently,
none of the literature examining individual MN excitability in SOD mice focus on this
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key time point. In addition, the few studies that examine the spinal MN network in SOD
mice focus solely on the sensory inputs. Our data helps explain the inconsistencies within
the literature surrounding individual MN excitability in ALS, provides additional
information about disease versus compensatory mechanisms in ALS, and reveals novel
information about the effects of ALS on the spinal MN network.
Small-Conductance Calcium-Activated Potassium (SK) Channels
More than 70 years ago, researchers discovered that the injection of bee venom or
apamin is toxic and detrimental to the nervous system (Habermann, 1984) due to the
blockage of voltage insensitive potassium channels (Hugues et al., 1982). These channels
are gated directly by concentrations of intracellular calcium and were identified as SK
channels (Blatz & Magleby, 1986). SK channels are expressed in a variety of neurons,
such as neurosecretory neurons in the supraoptic area of the hypothalamus (Bourque &
Brown, 1987), pyramidal neurons in the sensory cortex (Schwindt et al., 1988), striatal
cholinergic interneurons (Goldberg & Wilson, 2005), and spinal MNs (Zhang &
Krnjević, 1987).
In most neurons, APs are followed by a prolonged afterhyperpolarization (AHP)
(Barrett & Barret, 1976), which influences their intrinsic excitability (Adelman et al.,
2012). The AHP influences the voltage trajectory between APs and subsequently sets the
frequency of cell firing or the discharge rate (Adelman et al., 2012). In addition, the
summation of the AHP over a burst of APs can block AP firing, which is known as spike
frequency adaptation (Madison & Nicoll, 1982). The AHP has three components based
on differing kinetics, fast (f), medium (m), and slow (s) (Sah, 1996). The mAHP is
activated rapidly and decays within several hundred milliseconds (Adelman et al., 2012).
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It is blocked by apamin (Avanzini et al., 1989; Bourque & Brown, 1987; Sah &
McLachlan, 1992; Schwindt et al., 1988; Zhang & Krnjević, 1987; Zhang & McBain,
1995), lowering the external calcium concentration (Viana et al., 1993), or replacing
calcium with magnesium ions (Viana et al., 1993) and is thus a component regulated by
SK channel activity.
SK channels in MNs
In spinal MNs, SK channels are located on the proximal dendrites and soma.
Dendritic SK channels are activated by persistent L-type calcium channels and NMDA
receptors and regulate synaptic inputs, transmission, and plasticity (Faber et al., 2005; Li
& Bennett, 2007; Lin et al., 2008; Luján et al., 2009; Nanou et al., 2013). On the other
hand, somatic SK channels are activated by transient N-type calcium channels and
mediate the mAHP and MN firing (Deardorff et al., 2014; Li & Bennett, 2007; Ransom et
al., 1975; Viana et al., 1993).
The duration of the AHP differs between MN subtypes and exhibits a correlation
with the muscle fibers innervated by a particular MN (Bakels & Kernell, 1993; Burke,
1967; Gardiner, 1993). The F-type MNs, which innervate the fast twitch fibers, have the
shortest AHP which allows them to fire at higher rates compared to S-type MNs that
innervate the slow twitch fibers. Thus, the duration of the AHP in a MN is matched to the
contractile speed of the muscle fiber it innervates. Different MN subtypes also exhibit
different expression patterns of the various SK channel isoforms. There are four SK
channel isoforms, but only three of them, SK1, SK2, and SK3, exhibit differential
sensitivity to apamin (Gu et al., 2018; Ishii et al., 1997; Köhler et al., 1996; Shah &
Haylett, 2000; Strøbaek et al., 2000). Presently, much of the literature examining spinal
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MNs focuses on the SK2 and SK3 channel isoforms due to the lack of antibodies against
SK1 (Deardorff et al., 2013). Previous literature found that all MNs express SK2
channels, but only small, presumably S-type MNs exhibit SK3 channel expression
(Deardorff et al., 2013).
Possible role of SK channels in ALS
In ALS, F-type MNs die before S-type MNs (Hegedus et al., 2008; Pun et al.,
2006). This degeneration differential suggests that S-type MNs exhibit some
characteristics that decrease their vulnerability to disease mechanisms. MN subtypes
exhibit a difference in their intrinsic expression of SK channels and SK channels regulate
MN excitability; thus, SK channels may explain the vulnerability differential between F
and S-type MNs in ALS.
To date, SK channels have not been directly implicated in ALS, but Riluzole, the
primary ALS treatment, activates SK channels in recombinant expression systems and
hippocampal neurons (Bellingham, 2011; Cao et al., 2002; Grunnet et al., 2001). In
addition, N-type calcium channels, which activate SK channels, are overexpressed in
SOD cortical neurons and spinal MNs (Chang & Martin, 2016; Pieri et al., 2013). These
data, along with the limited therapeutic options and inconsistencies within the literature
regarding MN excitability at both the cellular and system levels, led our lab to examine
the role of SK channels in ALS using computer modeling, immunohistochemistry, and
drug studies. From our initial investigations, we determined that SK channels are
downregulated in neonatal SOD MNs and these changes persist throughout disease
progression and likely contribute to ALS pathogenesis (Dukkipati, 2016). Thereafter, we
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tested the therapeutic potential of an SK channel activator or positive modulator, CyPPA,
in SOD mice.
CyPPA selectively stimulates SK2 and SK3 channel activity but exhibits no
effects on SK1 or intermediate-conductance calcium-activated potassium (IK) channels
(Hougaard et al., 2007). CyPPA administration in dopaminergic (DA) neurons of the
substantia nigra pars compacta (SNc) results in decreased spontaneous firing and
prolonged duration of the mAHP and may be a potential method of pharmacological
modulation in psychiatric disorders, such as schizophrenia or attention-deficit
hyperactivity disorder (ADHD) (Herrik et al., 2012). CyPPA administration has also been
shown to suppress melanogenesis by downregulating microphthalmia-associated
transcription factor (MITF) (Noh et al., 2019), which is the most important target in the
treatment of hyperpigmentation disorders (Primot et al., 2010).
In our study, we administered CyPPA in SOD mice from P5-P20 in order to
overlap drug administration with the following: normal ion channel maturation, the ages
associated with our initial investigations, and the earliest documented morphological and
N-type calcium changes in SOD mice. Early treatment with CyPPA sustained motor
function and improved survival in SOD mice by 10 days (Dancy, 2017), which is fairly
comparable to the therapeutic effects of Riluzole in these mice. To date, Riluzole
treatment alone significantly prolongs the lifespan of SOD mice by 9-14 days
(Bellingham, 2011; Del Signore et al., 2009; Gurney et al., 1996; Gurney et al., 1998).
Together, these studies established the therapeutic potential of SK channels in
ALS, but the mechanism underlying the prolonged effects of this drug was still unknown.
Therefore, we conducted additional immunohistochemistry studies to examine the
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cellular mechanisms underlying the therapeutic benefits of CyPPA in SOD mice. These
data revealed that CyPPA restored the somatic clustering profile (area, density, and
intensity) of SK channels in SOD MNs and maintained these changes for up to 70 days
following treatment (Murphy, 2020). Yet, the effects of CyPPA on the excitability of
SOD MNs at the individual and network levels remained unknown. In Chapter V of the
current study, we investigated this gap in knowledge.
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Chapter III: General Methods
Animals
All electrophysiology data from individual MNs and the spinal MN network were
recorded in vitro from sacrocaudal spinal cord tissue obtained from male SOD1G93AHigh-Copy (SOD) mice at symptom onset (approximately postnatal day (P) 90) and
their age-matched wild-type (WT) transgenic littermates. Originally, mice were obtained
from Jackson Laboratory (Bar Harbor, ME) and then bred in our colony at Wright State
University (WSU). Only male mice were used in order to eliminate the confounds of
gender-related variability in disease onset, progression, and phenotype (Blasco et al.,
2012; Cacabelos et al., 2016; Choi et al., 2008; Veldink et al., 2003). Males also have a
higher prevalence of Amyotrophic lateral sclerosis (ALS) compared to females (Kurtzke,
1982; Logroscino et al., 2010). All surgical and experimental procedures were reviewed
and approved by the WSU Animal Care and Use Committee.
In Vitro Sacrocaudal Spinal Cord Preparation
In order to isolate the sacrocaudal spinal cord from all mice, we followed a
combination of the procedures detailed in previous publications (Jiang et al., 2017;
Mahrous et al., 2019) and outlined in Figure 1. Animals were deeply anesthetized with
intraperitoneal (IP) injections of urethane (0.15g/100g for SOD mice and 0.18 g/100g for
WT mice) and supplemental anesthetic was given as needed. Once each animal was no
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longer responsive to toe pinching, it was placed in a dissection dish in ventral
recumbency and supplied with carbogen (a mixture of carbon dioxide and oxygen gas in
the following proportions: 95% O2 and 5% CO2) through a face mask. The skin on the
back of each mouse was opened and the muscles attached to the vertebral column were
carefully separated. The spinal cord was then exposed via dorsal laminectomy and
longitudinal incision of the dura mater. During this time, the spinal cord was
continuously perfused with modified artificial cerebrospinal fluid (mACSF) aerated with
carbogen at a rate of approximately 6-7 ml/min.
Afterwards, each mouse was decapitated, and the spinal cord was transected at the
L4 segment. The spinal cord was carefully raised up and the dorsal and ventral roots of
the sacral and caudal regions were cut at their spinal outlets. The isolated spinal cord,
with attached roots, was transferred to a Petri dish filled with mACSF aerated with
carbogen. In the Petri dish, the dorsal and ventral spinal roots were separated and cleaned
of any remaining dura mater. Lastly, the spinal cord was moved to a recording chamber
and pinned ventral side upward. The recording chamber was continuously perfused with
normal ACSF (nACSF) at a rate of 2.5-3 ml/min. Both ventral and dorsal roots were
mounted on bipolar wire electrodes on the left and right sides of the recording chamber
and immediately covered with petroleum jelly to prevent desiccation. Before any
recordings were started, the spinal cord tissue was allowed to recover for approximately 1
hour in order to stabilize activity and wash out any residual anesthetic. This entire
procedure was performed at room temperature (21C).
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Physiological Solutions
Normal artificial cerebrospinal fluid (nACSF)
The nACSF contained the following (in mM): 128 NaCl, 3 KCl, 1.5 MgSO4, 1
NaH2PO4, 2.5 CaCl2, 22 NaHCO3, and 12 glucose. The osmolarity of the solution was
approximately 295 mOsm and the pH was 7.35-7.4 when aerated with carbogen.
Modified artificial cerebrospinal fluid (mACSF)
Compared to the nACSF, the mACSF contained higher amounts of magnesium to
block NMDA receptors and reduce cellular damage induced during spinal cord dissection
and isolation. Specifically, the mACSF contained the following (in mM): 118 NaCl, 3
KCl, 1.3 MgSO4, 5 MgCl2, 1.4 NaH2PO4, 1.5 CaCl2, 24 NaHCO3, and 25 glucose. The
osmolarity of the solution was approximately 310 mOsm and the pH was 7.35-7.4 when
aerated with carbogen.
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Figure 1: In vitro sacrocaudal spinal cord preparation
The skin on the back of each mouse is removed and the layers of muscle surrounding the
vertebral column are detached (A-B). Modified from Husch, Cramer, and HarrisWarrick (2011). The spinal cord is then exposed via dorsal laminectomy and longitudinal
incision of the dura mater (C). The spinal cord, along with the ventral and dorsal roots at
the sacral and caudal region, is carefully cut out (D) and placed into a Petri dish
containing mACSF aerated with carbogen (E). In the Petri dish, any remaining dura
mater is removed, and the ventral and dorsal roots are separated. The spinal cord is
transferred to a recording chamber perfused with nACSF aerated with carbogen (F). The
ventral and dorsal roots are mounted onto bipolar wire electrodes and covered with
petroleum jelly, as indicated by the green and red arrows, respectively.
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Electrophysiology Recordings
Intracellular recordings
Intracellular recordings were made from single motorneurons (MNs) while the
whole sacrocaudal spinal cord was maintained intact (Figure 2). Sharp intracellular
electrodes were pulled using a micropipette puller (P97, Sutter instruments, CA) and
filled with 3M potassium acetate with 100 mM KCl. Each electrode, with a resistance of
25-40 M, was advanced into the ventral horn of the spinal cord using a micro-positioner
(2660, Kopf instruments, CA). Single cell recordings were sampled at 20 kHz and lowpass filtered at 3 kHz with an Axoclamp-2A or 2B amplifier (Molecular Devices, CA)
running in bridge or discontinuous current clamp (DCC) modes. The outputs of the
amplifiers were digitized using Power 1401-3 data acquisition interface (CED, UK) at
10-20 kHz. All data was acquired into a computer controlled by Spike2 software (version
8.06, CED) and stored offline for analysis.
MNs were identified by the presence of an antidromic action potential (AP)
following ventral root stimulation. Cells with an unstable or depolarized resting
membrane potential (RMP) were excluded. For each cell, we measured passive
membrane properties, AP and afterhyperpolarization (AHP) properties, and repetitive
firing behavior. The following passive membrane properties were recorded: RMP, input
resistance (Rin) and its inverse input conductance (Gin), the time constant (tau),
capacitance, and rheobase. RMP was documented after each cell was stabilized. Rin and
Gin were measured as the slope of the linear portion of the current-voltage (I-V)
relationship derived from a series of hyperpolarizing 500 ms current pulses from -1 to 0.25 nA. Tau was also determined from the 500 ms hyperpolarizing pulses during the
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return to RMP using the graphical peeling method (Rall, 1969). The capacitance was
calculated by dividing tau by Rin. Finally, rheobase, defined as the minimum amount of
current necessary to evoke a single AP, was obtained from depolarizing 50 ms current
pulses in increasing increments of 0.2 nA.
For the AP parameters, we measured the AP height, maximum rising slope,
average rising slope, max falling slope, average falling slope, half-width, width, and time
to rise or peak. For the AHP parameters, we measured the AHP amplitude, time to rise,
half-decay, two-thirds decay, half-duration and conductance, which is denoted as GSK
because SK channels largely mediate the AHP. Since SK channels are not voltage
dependent and instead activated via intracellular calcium, their activity cannot be
measured experimentally but must be estimated from their ionic current amplitude (ISK)
using the following equation as described in Li and Bennett (2007):
ISK = GSK (V-EK)
𝐴𝐻𝑃𝑠𝑙𝑜𝑝𝑒

GSK = Gin (1−𝐴𝐻𝑃𝑠𝑙𝑜𝑝𝑒)

(1)
(2)

where the GSK is the AHP conductance measured for each cell, V is the potential
at the AHP peak, AHPslope is the slope of the regression line fit through the AHP vs.
holding potential relation, which is established by measuring the AHP amplitude from
antidromic evoked spikes while varying the membrane potential systematically with bias
currents (Li & Bennett, 2007), Gin is the input conductance of each cell, and EK is the
reversal potential for potassium, which is the holding potential at which the AHP
amplitude is zero. After GSK was calculated, we divided the GSK by capacitance, which is
directly correlated with cell size (Koch, 2004). Measurements of capacitance are often
used to normalize for variability in cell size in neurons (Schulz et al., 2006; Swensen &
Bean, 2005; Turrigiano et al., 1995) and changes in ionic conductance are expressed as
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conductance densities to reflect this standardization (Iwasaki et al., 2008; Khorkova &
Golowasch, 2007; Pineda et al., 2008; Zhang et al., 2019). In our study, this parameter is
identified as GSK density.
Lastly, we assessed firing behavior using intracellular injections of a series of
long (2 s) depolarizing current pulses of increasing amplitude (1.5-2.5 times the cellular
rheobase which is denoted as 1.5-2.5xR) and triangular current ramps with a constant
speed of 0.25 nA/s. With long current pulses, we measured the following: slope of the
regression line fitted to the membrane potential during the interspike interval (ISI) over
time curve or the ISI slope, the membrane potential during the ISI or ISI voltage, firing
frequency, maximum rising slope, maximum falling slope, and AP half-width. With
triangular current ramps, we measured Ion (the current level at firing onset), Ioff (the
current level at firing cessation), deltaI (Ioff - Ion), maximum firing frequency, and the
frequency-current (F-I) gain, the ascending (F-IAsc) and descending (F-IDesc) slopes of the
F-I relationship.
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Figure 2: Experimental setup for intracellular recordings from MNs
The spinal cord is placed ventral side up in a recording chamber perfused with nACSF
aerated with carbogen. MNs are impaled by sharp electrodes and identified by the
presence of an antidromic AP. Modified from Mahrous, Mousa, and Elbasiouny (2019).
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Ventral root recordings
The protocol for ventral root recordings was previously outlined in Mahrous and
Elbasiouny (2019). Both ventral and dorsal roots were mounted on bipolar wire
electrodes (Figure 3) and connected to a custom-built six-channel amplifier (Kinetic
Software, GA) in differential mode with 1000 times gain. All recordings were low pass
filtered at 3 kHz and high pass filtered at 300 Hz and performed at the S3-CO2 segments
where the responses or compound action potentials (coAPs) were most stable.
Sensory and descending motor inputs in the sacrocaudal spinal cord
Sensory input (S) was induced by electrical stimulation of the dorsal roots. Dorsal
roots were connected through bipolar wire electrodes (Figure 3A) to a stimulator (Isoflex,
AMPI) and stimulated with a train of five brief (0.1 ms) pulses at either 1.5 or 10-times
threshold (1.5 or 10xT) with a frequency of 0.06 or 25 Hz. The threshold for sensory
input was defined as the smallest amount of current needed to stimulate the dorsal roots
in order to produce a minimal response or coAP in the ventral roots (Figure 3B). This
value was on average 3.71 µA  2.42 SD in WT mice, 3.08 µA  1.23 SD in SOD mice,
and 3.25 µA  1.19 SD in SOD mice treated with CyPPA, denoted as SOD-CyPPA mice.
Descending motor input (M) was induced by electrical stimulation of the
remaining descending axons in the spinal cord (Figure 3C), which primarily originate
from the lateral vestibular nucleus, oral pontine reticular nucleus, and gigantocellular
reticular formation (Jiang et al., 2015; Liang et al., 2014; Liang et al., 2015, 2016). A
custom-built concentric bipolar electrode (0.125 mm stainless steel contact diameter
insulated by Teflon from a stainless-steel tube 0.2 ID/0.35 OD) was placed on the ventral
surface of the spinal cord close to the midline at the S3 segment and a train of five 0.1 ms
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electrical pulses were delivered through the electrode at 1.5 or 10xT with a frequency of
0.06 or 25 Hz. The threshold for descending motor input was defined as the smallest
amount of current needed to pass through the concentric electrode to produce a coAP in
the ventral roots. This value was on average 106.67 µA  63.01 SD in WT mice, 154.58
µA  109.24 SD in SOD mice, and 106.77 µA  73.59 SD in SOD-CyPPA mice. CoAPs
were evoked by stimulation of sensory and descending motor inputs separately and then
simultaneously (S&M) to study sensorimotor integration, as synaptic potentials generated
from these two inputs have similar delays 5 and thus reach the soma of MNs
synchronously (Mahrous et al., 2019). Descending motor inputs also exhibit a gradual
decay, which increases the overlap between these inputs when they are stimulated
concurrently (Mahrous et al., 2019).
Repetitive stimulation of sensory or descending motor inputs at frequencies lower
than 0.2 Hz results in weak or minimal synaptic plasticity (Jiang et al., 2015). Thus, the
five evoked coAPs following repetitive stimulation of sensory inputs, descending motor
inputs, or both inputs simultaneously at 0.06 Hz were almost identical in size and
therefore averaged together to measure coAP amplitude6. Repetitive stimulation of
sensory or descending motor inputs at frequencies between 25 and 100 Hz induces
system short-term plasticity (depression or facilitation) in coAPs (Jiang et al., 2015). As a
result, repetitive stimulation at 25 Hz was used to study these adaptation patterns in both
synaptic inputs and sensorimotor integration.

5

Time from the stimulus trigger to the onset of the rising phase of the excitatory postsynaptic potential
(EPSP)
6
Peak-to-peak value
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Plasticity (system short-term depression (sSTD) or facilitation (sSTF)) in coAPs
was quantified by converting the amplitudes of coAPs into percent changes from the
amplitudes of their respective, first evoked coAP. In addition, the amount of sensorimotor
integration was determined by subtracting the linear summation of the individual inputs
(S+M) at each pulse from the evoked coAPs in response to both inputs stimulated
simultaneously (S&M), as normal S&M stimulation follows a supralinear trend (Mahrous
et al., 2019).
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Figure 3: Experimental setup for ventral root recordings from the spinal MN
network
The dorsal roots (A) are connected to a stimulator while the ventral roots are connected to
a multichannel extracellular amplifier (B) for recording. A concentric electrode (C) is
placed on the ventral side of the spinal cord tissue to stimulate the remaining descending
axons. Modified from Mahrous, Mousa, and Elbasiouny (2019).
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CyPPA Treatment in SOD Mice
CyPPA, a selective positive modulator of small-conductance calcium-activated
potassium (SK) channel isoforms two and three or SK2 and SK3 (Hougaard et al., 2007),
was administered to SOD mice for 16 days (P5-P20) within the same three-hour time
frame each day. This drug was purchased from Sigma-Aldrich (CAT No. 5493 Lot
#075U4604V) and given through IP injections at 14.6 mg/kg. Later, at approximately
P90, these mice underwent the same surgery and electrophysiology protocols as
previously described. These mice are denoted as SOD-CyPPA mice.
Statistical Analyses
All statistical analyses were performed using IBM SPSS Statistics (Armonk, New
York, Version 26) and SAS (Cary, North Carolina). All graphs were constructed using
Origin Pro (Wellesley Hills, Massachusetts, Version 2021). In order to study the effects
of genotype (SOD vs. WT) and treatment with CyPPA (SOD-CyPPA) on passive
membrane properties, AP and AHP properties, and repetitive firing behavior measured
using triangular current ramps, a one-way ANOVA with a Tukey’s or Games-Howell
post-hoc test or a Kruskal Wallis test was performed depending on normality. When
possible, non-normal data was transformed using the natural logarithm.
In order to study the effects of genotype and treatment with CyPPA on repetitive
firing behavior measured with long current pulses of increasing amplitudes, a two-way
mixed ANOVA was conducted in SAS. This was due to the fact that some cells had a
higher repetitive firing threshold, and thus did not fire at all three time points or pulses,
resulting in some missing values. Unlike SPSS, SAS is not influenced by missing values
when conducting a mixed analysis.
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To study the effects of genotype and treatment with CyPPA and intensity (1.5 or
10xT) on the amplitude of coAPs generated following stimulation of each synaptic input
and both synaptic inputs simultaneously at 0.06 Hz, a two-way ANOVA was used.
Lastly, to study the effects of genotype and treatment with CyPPA at each intensity on
sSTD, sSTF, and sensorimotor integration, a two-way mixed ANOVA was performed.
In all two-way ANOVAs, the design was unbalanced and thus a Bonferroni
multiple comparisons test was used to interpret main effects rather than Tukey’s post-hoc
test. This test was also used for the mixed ANOVA models. A p value < 0.05 was
considered statistically significant for all analyses. All statistical tests were conducted
once, but the results are presented in increments focusing on the post-hoc results or
pairwise comparisons between SOD and WT data (Chapter IV) and then SOD-CyPPA
data relative to SOD and WT data (Chapter V). Thus, the SOD and WT data discussed in
Chapter V is the same SOD and WT data from Chapter IV.
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Chapter IV: Specific Aim 1
Amyotrophic Lateral Sclerosis (ALS)-induced excitability changes in
individual motorneurons (MNs) and the spinal MN network in SOD1G93AHigh-Copy (SOD) mice at symptom onset
The overall objective of Specific Aim 1 was to examine the excitability state of
individual MNs and the spinal MN network in SOD mice at symptom onset.
Introduction
ALS is the most common MN disorder and it was first described by French
neurologist Jean-Martin Charcot in 1869 (Katz et al., 2015). ALS is characterized by the
progressive degeneration of both upper and lower MNs at the spinal or bulbar levels
(Rowland & Shneider, 2001). Most ALS cases are sporadic and only 5-10 percent of ALS
cases have a familial link (R. Bonafede & R. Mariotti, 2017). The etiology of ALS is still
poorly understood, but years of research has demonstrated the involvement of several
altered signaling pathways with the most longstanding being glutamate excitotoxicity
(Morgan & Orrell, 2016; Rothstein et al., 1990). ALS’s association with glutamate
excitotoxicity dates back to the 1990s when Rothstein and his colleagues discovered an
abnormal amount of glutamate analogs in the cerebrospinal fluid (CSF) of ALS patients.
The current excitotoxicity theory predicts that MN death in ALS results from excessive
MN activation via glutamate (Shaw & Ince, 1997). This hyperexcitability of MNs leads
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to high levels of calcium entering these cells, which triggers apoptosis. This hypothesis is
supported by the discovery that MNs are extremely sensitive to increased glutamate
activity (Carriedo et al., 1996; Rothstein et al., 1993; Van Den Bosch et al., 2000). The
first approved treatment for ALS, Riluzole, also has anti-excitotoxic properties
(Bensimon et al., 1994; Lacomblez et al., 1996). Yet, the research examining the
excitability state of MNs in ALS is inconsistent. These studies provide evidence of
hyperexcitability, hypoexcitability, and no change in the excitability of MNs in ALS
(Delestrée et al., 2014; Jensen et al., 2020; Martínez-Silva et al., 2018; Quinlan et al.,
2011). These conflicting results could be attributed to experimental design and/or disease
and compensatory processes having opposing effects on MN excitability.
To date, most ALS research on alterations in MN excitability focus primarily on
individual MNs, but excitotoxicity in ALS could emerge from an increase or decrease in
the activity of neurons that synapse onto MNs. Additionally, it is the output of the spinal
MN network which drives muscle activity, a major deficit in ALS patients. In the spinal
cord, three inputs regulate the firing pattern of MNs, sensory inputs from the periphery,
descending motor inputs from supraspinal structures, and local interneuronal inputs
within the spinal cord (Carp & Wolpaw, 2010).
The integration of these inputs allows for the generation of stable motor outputs
for any given motor task (Kim et al., 2017; Nielsen, 2004; Rossignol et al., 2006); and
this complex process is influenced by synaptic plasticity (depression or facilitation).
Following successive stimulation, sensory inputs exhibit system short-term depression
(sSTD), while descending motor inputs exhibit frequency-dependent bimodal plasticity,
favoring system-short term facilitation (sSTF) at high-stimulation frequencies (Jiang et
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al., 2015). The few research studies examining MN excitability in ALS at the system or
spinal MN network level only focus on sensory inputs and present conflicting results.
Currently, the state of the literature regarding MN excitability in ALS at the
individual and network levels is inconclusive. As a result, this study investigated ALSinduced excitability changes in individual MNs and the spinal MN network in the
standard mouse model of ALS, SOD mice, at symptom onset. In individual MNs, we
assessed passive membrane properties, action potential (AP) and afterhyperpolarization
(AHP) properties, and repetitive firing behavior, all factors that contribute to MN
excitability. At the level of the spinal MN network, both sensory and descending motor
inputs were examined separately, along with their integration.
Results
Specific Aim 1A: ALS-induced excitability changes in individual MNs in SOD mice
at symptom onset
SOD MNs exhibit hypoexcitable changes in passive membrane properties at symptom
onset
MN excitability is influenced by numerous interacting cellular properties or “subcomponents”, some passive and others active or a result of ion channel conductance. To
determine the effects of ALS on passive membrane properties at symptom onset, we
measured resting membrane potential (RMP), input resistance (Rin), input conductance
(Gin), the time constant (tau), capacitance, and rheobase in MNs from 29 SOD (92.08
days  4.20 SD, actual range: 85-103) and 22 WT (93.61 days  2.80 SD, actual range:
87-101) mice. SOD and WT MNs both displayed an average RMP of -72 mV (Figure
4A). However, SOD MNs exhibited a significant decrease in Rin (Figure 4B, WT 12.87

42

M  2.70 SD vs. SOD 10.75 M  3.82 SD, p = 0.036) and a significant increase in Gin
(Figure 4C, WT 0.08 μS  0.02 SD vs. SOD 0.11 μS  0.04 SD, p = 0.004). While there
were no significant differences in tau (Figure 4D), SOD MNs exhibited a significant
increase in capacitance (Figure 4E, WT 0.13 nF  0.04 SD vs. SOD 0.19 nF  0.08 SD, p
= 0.004) which further confirms previous research that ALS causes an increase in the size
of MNs (Amendola & Durand, 2008; Dukkipati et al., 2018; Shoenfeld et al., 2014).
Despite these changes, rheobase values were comparable between SOD and WT MNs
(Figure 4F). Collectively, the changes in passive membrane properties in SOD MNs at
symptom onset suggest hypoexcitability. All measured passive membrane properties are
summarized in Table 1.
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Figure 4: SOD MNs exhibit hypoexcitable changes in passive membrane properties
at symptom onset
Passive membrane properties were measured in MNs from SOD and WT mice at or
around postnatal day (P) 90, which is symptom onset in the SOD rodent model of ALS.
(A) On average, both SOD and WT MNs had a RMP of -72 mV. SOD MNs exhibited a
significant decrease in Rin (B) and a significant increase in Gin (C). While SOD and WT
MNs had similar tau measurements (D), SOD MNs were significantly larger according to
capacitance measurements (E). However, rheobase values were comparable between
SOD and WT MNs (F). The bars represent the mean  SD. Significant differences are
shown (*, p < 0.05 and **, p < 0.01; Games-Howell post-hoc tests).
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RMP, mV

WT
-72.42 ± 8.48

SOD
-72.28 ± 6.81

Rin, MΩ

12.87 ± 2.70

10.75 ± 3.82*

Gin, μS
Tau, ms
Capacitance, nF

0.08 ± 0.02
1.65 ± 0.37
0.13 ± 0.04

0.11 ± 0.04**
1.94 ± 0.63
0.19 ± 0.08**

Rheobase, nA

2.12 ± 1.11

3.00 ± 1.64

mean  SD, *p < 0.05, **p < 0.01

Table 1. Passive membrane properties
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SOD MNs exhibit no changes in AP properties, but hyperexcitable changes in AHP
properties at symptom onset
Another important contributor to MN excitability is AP and AHP properties, also
known as active properties, because they are determined by various ion channels. To
study the effects of ALS on AP and AHP properties, we measured a total of 13 properties
(AP height, maximum and average rising slopes, maximum and average falling slopes,
half-width, width, time to rise and AHP amplitude, time to rise, half-decay, two-thirds
decay, and half-duration) and estimated SK channel conductance (GSK density) using the
calculation outlined in the methods section. There were no significant differences in any
AP properties between SOD and WT MNs (Figure 5, Table 2). These same trends were
found in some AHP properties including AHP time to rise, half decay, two-thirds decay,
and half-duration (Table 3).
Nonetheless, SOD MNs exhibited a significant 24 percent reduction in AHP
amplitude (Figure 6, WT 2.30 mV  0.86 SD vs. SOD 1.74 mV  0.75 SD, p = 0.038).
The AHP is mediated via SK channels and thus AHP amplitude is determined by GSK
density. Expectedly, SOD MNs also exhibited a significant decrease in GSK density
(Figure 7A, WT 0.15 S/nF  0.06 SD vs. SOD 0.11 S/nF  0.13 SD). GSK density data
was non-normal and thus transformed using the natural logarithm (Figure 7B, p = 0.016),
but for clarity, original mean values are reported. Together, these results support
hyperexcitability in SOD MNs at symptom onset. Additionally, our data supports recent
immunohistochemistry studies which determined that SK channels are significantly
reduced in SOD mice throughout ALS disease progression (Dukkipati, 2016; Murphy,
2020).
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Figure 5. SOD MNs do not show any alterations in AP properties at symptom onset
Superimposition of representative sample APs recorded near rheobase for a WT (blue)
and SOD (red) MN.
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WT

SOD

AP height, mV
Maximum rising slope, V/s

63.03 ± 10.81
87.27 ± 33.08

62.63 ± 9.70
85.98 ± 34.76

Average rising slope, V/s

44.60 ± 14.63

44.61 ± 16.04

Maximum falling slope, V/s

-71.91 ± 14.27

-70.00 ± 16.51

Average falling slope, V/s

-33.97 ± 8.03

-34.03 ± 9.97

AP half-width, ms

1.24 ± 0.19

1.23 ± 0.17

AP width, ms

3.22 ± 0.58

3.15 ± 0.61

AP time to rise, ms

1.42 ± 0.30

1.45 ± 0.39

Table 2. AP properties
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Figure 6. SOD MNs exhibit a significant reduction in AHP amplitude at symptom
onset
(A) Superimposition of representative sample AHPs recorded on isolated APs from a WT
(blue) and SOD (red) MN. (B) At symptom onset, SOD MNs exhibited a significant
reduction in AHP amplitude compared to their WT littermates. Bars represent the mean 
SD. Statistical difference indicated (*, p < 0.05; Tukey’s post-hoc test).
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Figure 7. SOD MNs exhibit a significant reduction in GSK density at symptom onset
SOD MNs exhibited a significant reduction in GSK density compared to WT MNs. Both
original (A) and transformed (B) mean values are reported, as GSK density had a nonnormal distribution. The original values were transformed using the natural logarithm.
The bars represent the mean  SD. Statistical difference indicated (*, p < 0.05; Tukey’s
post-hoc test).
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AHP amplitude, mV
AHP time to rise, ms
AHP half-decay, ms
AHP two-thirds decay, ms
AHP half-duration, ms
GSK density, S/nF
GSK density transformed

WT
2.30 ± 0.86
12.73 ± 4.72
19.99 ± 8.10
53.87 ± 18.01
29.92 ± 10.93
0.15  0.06
-0.86  0.19

Table 3. AHP properties
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SOD
1.74 ± 0.75*
11.89 ± 4.23
19.35 ± 9.01
59.50 ± 21.35
27.87 ± 10.62
0.11  0.13
-1.10  0.33*

mean  SD, *p < 0.05

During repetitive firing, SOD MNs exhibit a consistent rate of decrease or
hyperpolarization in the membrane potential during the interspike interval (ISI)
To study repetitive firing behavior, we first used long (2 s) current pulses of
increasing amplitudes (1.5-2.5 times the cellular rheobase or 1.5-2.5xR) (Figure 8).
During each current pulse, we measured ISI slope (rate of change in the membrane
potential during the ISI), ISI voltage (the membrane potential during the ISI), firing
frequency, maximum rising and falling slopes, and AP half-width.
Since the amount of current injected into each cell depended on rheobase, an
intrinsic cellular property, we controlled for these values during the statistical analysis.
For all measured parameters, there were no significant interactions between rheobase and
genotype. However, there were no main effects of genotype (Table 4), but there was a
statistically significant interaction between genotype and current pulse for ISI slope (p =
0.033). Specifically, WT MNs exhibited a significant increase in ISI slope with
increasing current pulse intensity (Figure 9, Table 4). At 1.5xR current pulses, the ISI
voltage in WT MNs decreased or hyperpolarized at a rate of 0.39 mV per second.
However, at 2- and 2.5xR current pulses, the ISI voltage in WT MNs increased or
depolarized at a rate of 1.23 or 0.99 mV per second, respectively. Similar changes were
not observed in SOD MNs which maintained a steady negative ISI slope with increasing
current pulse amplitude. Together, these data show that at symptom onset, SOD MNs
exhibit a consistent rate of decrease or hyperpolarization in the ISI voltage during
repetitive firing.
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Figure 8. Repetitive firing induced by long (2 s) current pulses
Long depolarizing current pulses of amplitudes ranging from 1.5-2.5xR were injected
into MNs to study repetitive firing behavior. Shown are examples from a WT (A) and
SOD (B) MN.
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Maximum rising
slope, V/s

1.5xR
WT
SOD
-0.39 ±
-0.77 ±
0.49
0.27
-47.78 ±
-48.12 ±
2.64
2.37
24.18 ±
27.23 ±
1.26
1.20
59.75 ±
57.52 ±
1.33
1.64

WT
1.23 ±
0.85**
-43.94 ±
3.01
34.17 ±
1.70
57.79 ±
1.54

SOD
-0.82 ±
0.34
-46.85 ±
2.02
35.62 ±
1.76
54.64 ±
1.58

2.5xR
WT
SOD
0.99 ±
-1.00 ±
1.05*
0.38
-39.46 ±
-41.39 ±
4.29
3.87
41.39 ±
41.24 ±
2.10
2.46
54.61 ±
52.57 ±
1.99
1.68

Maximum falling
slope, V/s

-72.10 ±
2.42

-68.78 ±
1.81

-68.94 ±
2.56

-65.11 ±
2.22

-64.35 ±
3.00

-62.32 ±
2.33

AP half-width, ms

1.34 ±
0.03

1.30 ±
0.01

1.38 ±
0.03

1.34 ±
0.02

1.42 ±
0.05

1.37 ±
0.02

ISI slope, mV/s
ISI voltage, mV
Firing frequency, Hz

2xR

Table 4. Repetitive firing properties measured during long (2 s) current pulses
mean  SE, * p < 0.05, ** p < 0.01
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Figure 9. At symptom onset, SOD MNs exhibit a steady negative ISI slope during
repetitive firing
Compared to WT MNs, SOD MNs exhibited a steady negative ISI slope with increasing
current pulse amplitude. Thus, SOD MNs showed a consistent rate of decrease or
hyperpolarization in ISI voltage at each current pulse. WT MNs exhibited a significant
increase in ISI slope with increasing current pulse amplitude. At 1.5xR current pulses, the
ISI voltage in WT MNs decreased or hyperpolarized at a rate of 0.39 mV per second.
These rates significantly shifted at 2- and 2.5xR current pulses. At these current pulses,
the ISI voltage in WT MNs increased or depolarized at a rate of 1.23 or 0.99 mV per
second, respectively. Each data point represents the mean and error bars denote the SE.
Significant differences are shown (*, p < 0.05 and **, p < 0.01; Bonferroni multiple
comparisons test) and each asterisk indicates the difference from the first WT data point
at the 1.5xR current pulse.
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Frequency-current (F-I) gain is significantly reduced in SOD MNs at symptom onset
The repetitive firing behavior of MNs can be further characterized using
increasing and decreasing (triangular) current ramps. These ramps are typically used to
uncover the input-output relationship of MNs and the properties of persistent inward
currents (PICs) (Hounsgaard et al., 1988; Lee & Heckman, 1998). PICs are primarily
mediated via voltage-sensitive sodium and potassium channels located in the dendrites of
MNs (Carlin et al., 2000; Hounsgaard & Kiehn, 1993; Lee & Heckman, 1999; Li et al.,
2004). These channels increase the excitability of a MN and generate a greater output for
a given input (Heckman et al., 2009).
In order to study the effects of ALS on the input-output relationship and PICs in
MNs at symptom onset, we measured Ion (the current level at firing onset), Ioff (the
current level at firing cessation), deltaI (Ioff - Ion), maximum firing frequency, and the F-I
gain, the ascending (F-IAsc) and descending (F-IDesc) slopes of the F-I relationship, in
SOD and WT MNs using triangular current ramps with a constant speed of 0.25 nA/s
(Figure 10).
There were no significant differences in Ion, Ioff, maximum firing frequency, and
deltaI between SOD and WT MNs (Table 5). DeltaI values are typically used to estimate
total PICs and more negative values indicate the presence of a PIC. Thus, SOD MNs at
symptom onset do not demonstrate an alteration in PICs, but deltaI is an indirect and less
sensitive measurement of PICs (Quinlan et al., 2011). At symptom onset, SOD MNs
exhibited a significant decrease in F-IAsc (Figure 11, WT 7.96 Hz/nA  3.12 SD vs. SOD
5.21 Hz/nA  2.61 SD, p = 0.003). F-IDesc was also reduced in SOD MNs, but these
values were not significantly different from WT MNs.
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Many intrinsic MN properties impact the gain of the F-I function including PICs,
the AHP, and input conductance (Hounsgaard et al., 1988; Powers & Binder, 2001;
Rekling et al., 2000). As a result, F-I gain is typically referred to as the ‘net’ excitability
of a MN (Kuo et al., 2004; Kuo et al., 2005; Quinlan et al., 2011). Thus, despite both
hypoexcitable (reduced Rin and increased Gin and capacitance) and hyperexcitable
(reduced AHP amplitude and GSK density) changes in SOD MNs at symptom onset, the
net excitability of these cells is reduced and thus hypoexcitability predominates.
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Figure 10. Repetitive firing induced by triangular current ramps and frequencycurrent (F-I) relationships
Depolarizing ramps of current were injected into MNs to study the F-I relationship and
PICs. Shown are examples from a WT (A) and SOD (B) MN. The relationship between
firing frequency and current is plotted below each MN, labeled (C) and (D), respectively.
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WT

SOD

Ion, nA

2.97 ± 1.71

4.06 ± 2.66

Ioff, nA

2.83 ± 1.76

3.79 ± 3.25

0.14 ± 0.89
47.42 ± 17.44
7.96 ± 3.12

0.27 ± 1.15
41.77 ± 12.21
5.21 ± 2.61**

7.33 ± 3.56

6.27 ± 2.58

deltaI (Ioff - Ion)
Maximum firing frequency, Hz
F-IAsc, Hz/nA
F-IDesc, Hz/nA

Table 5. Repetitive firing properties measured during triangular current ramps
mean  SD, **p < 0.01
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Figure 11. SOD MNs exhibit a significant reduction in net excitability or F-I gain at
symptom onset
SOD MNs exhibited a significant reduction in F-IAsc at symptom onset compared to WT
MNs. Similar changes were observed in F-IDesc, but these values were not significantly
different from WT MNs. The bars represent the mean  SD. Statistical difference
indicated (**, p < 0.01; Tukey’s post-hoc test).
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Specific Aim 1B: ALS-induced excitability changes in the spinal MN network of
SOD mice at symptom onset
Sensory and descending motor inputs in the spinal MN network of SOD mice at
symptom onset do not contribute to MN excitability alterations
To investigate the excitability state of the spinal MN network in SOD mice at
symptom onset, we examined sensory and descending motor inputs in 12 SOD (93.20
days  2.88 SD, actual age range: 87-99) and 14 WT (95.50 days  5.33 SD, actual age
range: 86-110) mice. Specifically, we measured compound action potentials (coAPs)
evoked by repetitive stimulation (5-pulse train) of sensory (via dorsal roots) or
descending motor (via remaining descending axons in the spinal cord tissue) inputs at
frequencies of 0.06 or 25 Hz and intensities of 1.5 or 10-times threshold (1.5 or 10xT).
Threshold denotes the smallest amount of current needed to evoke a coAP. From these
measurements, we evaluated the amplitudes of evoked coAPs, which is proportional to
the number of cells activated by each synaptic input and the degree of system short-term
plasticity (depression or facilitation) produced in these responses, which represents a
form of excitability (Jiang et al., 2015).
All five coAPs that were evoked following sensory or descending motor input
stimulation at 0.06 Hz were averaged to examine differences in coAP amplitudes.
Surprisingly, evoked coAPs were comparable in SOD and WT mice for both synaptic
inputs irrespective of stimulation intensity (Figure 12 and 13). However, stimulation of
descending motor inputs at 10xT resulted in significantly larger coAPs for both
genotypes compared to 1.5xT stimulation (Figure 13B, p < 0.001). All coAP amplitude
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data was non-normal and thus transformed using the natural logarithm, but for clarity
original mean values are also reported.
Previous research has determined that sensory and descending motor inputs
produce different patterns of system short-term plasticity in motor outputs. High
frequency repetitive stimulation (25-100 Hz) of sensory inputs causes system short-term
depression (sSTD), while identical stimulation of descending motor inputs yields system
short-term facilitation (sSTF) (Jiang et al., 2015; Mahrous et al., 2019). Identical
adaptation patterns were present in both genotypes following stimulation of sensory
(sSTD) or descending motor (sSTF) inputs at 25 Hz (Figure 14 and 15). The degree of
sSTD and sSTF was quantified as outlined in the methods section. Sensory and
descending motor inputs in SOD and WT mice produced comparable amounts of sSTD
or sSTF, respectively (Figure 14 and 15). However, sSTD increased over the five pulses
of sensory input stimulation at 1.5 and 10xT in both SOD and WT mice (Figure 14, p <
0.001).
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Figure 12. Evoked coAPs following stimulation of sensory inputs in SOD mice at
symptom onset
Repetitive stimulation (0.06 Hz at 1.5 or 10xT) of sensory inputs evoked comparable
coAPs in WT and SOD mice. Both original (A) and transformed (B) mean values are
reported, as coAP amplitude data for sensory input stimulation had a non-normal
distribution. The original values were transformed using the natural logarithm. The bars
represent the mean  SD.
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Figure 13. Evoked coAPs following stimulation of descending motor inputs in SOD
mice at symptom onset
Repetitive stimulation (0.06 Hz at 1.5 or 10xT) of descending motor inputs evoked
comparable coAPs in WT and SOD mice. In addition, both WT and SOD mice exhibited
significantly larger coAPs in response to descending motor input stimulation at 10xT
compared to 1.5xT. Both original (A) and transformed (B) mean values are reported, as
coAP amplitude data for descending motor input stimulation had a non-normal
distribution. The original values were transformed using the natural logarithm. The bars
represent the mean  SD. Statistical differences are shown (***: WT 10xT vs. 1.5xT and
+++: SOD 10xT vs. 1.5xT, p < 0.001; Bonferroni multiple comparisons test).
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Figure 14. Sensory inputs exhibit normal sSTD in SOD mice at symptom onset
Sensory inputs in both WT (A) and SOD (B) mice showed sSTD following 25 Hz
repetitive stimulation at 1.5xT. These same adaptation patterns were also found at 10xT
(not pictured). At both stimulation intensities (C and D), sensory inputs exhibited
comparable amounts of sSTD in WT and SOD mice. However, the degree of sSTD
significantly increased over the five pulses of stimulation at both 1.5 and 10xT in WT and
SOD mice. Bars represent mean  SD. Statistical differences are shown (***: different
from WT P2 at 1.5 or 10xT and +++: different from SOD P2 at 1.5 or 10xT, p < 0.001;
Bonferroni multiple comparisons test).
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10xT

Figure 15. Descending motor inputs exhibit normal sSTF in SOD mice at symptom
onset
Descending motor inputs in both WT (A) and SOD (B) mice exhibited sSTF following 25
Hz repetitive stimulation at 1.5xT. These same adaptation patterns were also found at
10xT (not pictured). At both stimulation intensities (C and D), descending motor inputs
exhibited comparable amounts of sSTF in WT and SOD mice. Data is represented as
mean  SD.
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Sensorimotor integration is significantly impaired in SOD mice at symptom onset
Individually, sensory and descending motor inputs generate different patterns of
system short-term plasticity in motor output. Yet, the motor output of the spinal cord is
stable during most tasks and simultaneous stimulation of both sensory and descending
motor inputs produces similar responses or coAPs (Mahrous et al., 2019). Thus,
sensorimotor integration, the combination of both sensory inputs from the periphery and
descending motor commands from supraspinal structures, is necessary to produce
suitable motor output for any given motor task (Kim et al., 2017; Mahrous et al., 2019;
Rossignol et al., 2006). In ALS, motor function is significantly impaired, and the onset of
these deficits is primarily attributed to the progressive loss of MNs over the course of the
disease. However, the integration of sensory and descending motor inputs may also be
compromised and consequently contribute to the development of motor deficits in ALS.
To investigate the effects of ALS on sensorimotor integration at symptom onset,
we measured evoked coAPs or motor output following repetitive stimulation (5-pulse
train) of sensory (S) and descending motor (M) inputs simultaneously (S&M) at
frequencies of 0.06 or 25 Hz and intensities of 1.5 or 10xT in the same sample discussed
in the previous section. All five coAPs that were evoked following S&M stimulation at
0.06 Hz were averaged to examine differences in coAP amplitudes. SOD mice exhibited
smaller coAPs following S&M stimulation at 1.5xT, but these values were not
significantly different from WT mice. However, these differences reached statistical
significance at 10xT (Figure 16A, WT 14.28 mV  4.88 SD vs. SOD 8.09 mV  4.75
SD). S&M coAP amplitude data was non-normal and thus transformed using the natural
logarithm (Figure 16B, p = 0.008), but for clarity original mean values are reported.
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S&M stimulation at 25 Hz using 5-pulse trains produced stable motor output or
coAPs in both SOD and WT mice (Figure 17). In order to quantify sensorimotor
integration, we used the calculation outlined in the methods section. SOD mice exhibited
a significant deficit in sensorimotor integration at 1.5 and 10xT (Figure 17). In addition,
sensorimotor integration in WT mice was significantly amplified over the five pulses of
stimulation at both 1.5 and 10xT (p < 0.001). Sensorimotor integration data at 1.5xT
(Figure 17C) was non-normal and thus transformed using the natural logarithm.
Taken together, these data demonstrate that sensory and descending motor inputs
in SOD mice at symptom onset evoke normal motor output. Additionally, these inputs do
not contribute to MN excitability alterations at this time point, as stimulation of these
synaptic inputs separately results in comparable system short-term plasticity in the motor
output of SOD and WT mice. Despite apparently normal sensory and descending motor
inputs, SOD mice demonstrate a significant impairment in the integration of these inputs
at symptom onset.
In conclusion, the data in Specific Aim 1 of this dissertation showed for the first
time the state of individual MN excitability at symptom onset in SOD mice. Despite both
hypoexcitable and hyperexcitable changes in intrinsic properties, net excitability of SOD
MNs was reduced. In addition, the excitability state of the spinal MN network in SOD
mice at symptom onset was characterized. These studies revealed that sensory and
descending motor inputs to spinal MNs do not contribute to differences in SOD MN
excitability at symptom onset. These studies also discovered a new mechanism
contributing to the development of motor deficits in SOD mice at symptom onset,
impairments in sensorimotor integration.
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Figure 16. S&M stimulation evokes smaller coAPs in SOD mice at symptom onset
Simultaneous stimulation (0.06 Hz at 1.5 or 10xT) of sensory and descending motor
inputs evoked smaller coAPs in SOD mice at symptom onset at both 1.5 and 10xT, but
these differences were only statistically significant at 10xT. Both original (A) and
transformed (B) mean values are reported, as coAP amplitude data for simultaneous
stimulation of sensory and descending motor inputs had a non-normal distribution. The
original values were transformed using the natural logarithm. The bars represent the
mean  SD. Statistical difference indicated (**, p < 0.01; Bonferroni multiple
comparisons test).
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Figure 17. Integration of sensory and descending motor inputs is significantly
impaired in SOD mice at symptom onset
Simultaneous stimulation (25 Hz at 1.5xT) of sensory and descending motor inputs
evoked stable motor outputs in both WT (A) and SOD (B) mice. Similar patterns were
also observed at 10xT (not pictured). However, SOD mice exhibited a significant deficit
in sensorimotor integration at both 1.5 (C) and 10xT (D). Additionally, at both 1.5 and
10xT, sensorimotor integration was amplified in WT mice over the five pulses of
stimulation. Sensorimotor integration data at 1.5xT was non-normal and thus transformed
using the natural logarithm. The bars represent the mean  SD. Statistical differences are
indicated (*, p < 0.05, **, p < 0.01, and ***, p < 0.001; Bonferroni multiple comparisons
test). Asterisks over the WT bars are comparing WT P1 vs. WT P2-P5 and asterisks
above a single black bar are comparing differences between SOD and WT mice).
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Chapter V: Specific Aim 2
The long-term effects of early treatment of SOD1-G93AHigh-Copy (SOD)
mice with CyPPA on the excitability of individual motorneurons (MNs)
and the spinal MN network
The overall objective of Specific Aim 2 was to determine the long-term effects of early
treatment of SOD mice with CyPPA, an SK channel activator, on the excitability of MNs
at the individual and network levels.
Introduction
Currently, there are only two drugs approved to treat ALS in the United States,
Riluzole and Edaravone, but neither cures the disease nor improves quality of life in
patients (Jaiswal, 2019). Still, over 60 other molecules have been investigated as potential
treatments for ALS. However, many of these molecules delayed progression in
preclinical animal models of ALS but failed to show efficacy in human clinical trials
(Petrov et al., 2017). This disconnect between animal research and human clinical trials is
attributed to the complex and unknown etiology of ALS. Consequently, our lab began
investigating a new molecule likely involved in ALS, the small-conductance calciumactivated potassium (SK) channel. SK channels are unevenly expressed in MN subtypes
and regulate MN excitability via the afterhyperpolarization (AHP). Specifically,
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large or F-type MNs only express SK2 channels, while small or S-type MNs express both
SK2 and SK3 channel isoforms (Deardorff et al., 2013; Dukkipati et al., 2018). SK3
channels in S-type MNs primarily facilitate their longer duration/larger amplitude AHPs
(Elbasiouny laboratory, unpublished). Interestingly, S-type MNs are also less susceptible
to degeneration in ALS. Thus, differences in SK channels may underlie the vulnerability
differential of MN subtypes in ALS.
In order to study the role of SK channels in ALS, we initially used a high-fidelity
computational model of neonatal SOD MNs. These simulations found SK channel current
to be downregulated in SOD MNs (Elbasiouny laboratory, unpublished). Next, we
confirmed our simulations with immunohistochemistry studies which demonstrated SK
channel downregulation throughout disease progression in SOD MNs (Dukkipati, 2016).
These deficits were improved by early treatment (postnatal day (P) 5- P20) with CyPPA.
Treatment with CyPPA restored the somatic clustering profile of SK channels in SOD
MNs up to 70 days following treatment cessation (i.e., P90 or symptom onset) (Murphy,
2020). In addition, CyPPA treatment delayed motor function decline and prolonged
survival by 10 days in SOD mice (Dancy, 2017).
These data established the therapeutic potential of CyPPA in SOD mice but did
not elucidate the functional effects of CyPPA on the excitability of individual MNs and
the spinal MN network. Therefore, this study examined the long-term effects of early
treatment of SOD mice with CyPPA on the excitability of individual MNs and the spinal
MN network.
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Results
Specific Aim 2A: The long-term effects of early treatment of SOD mice with CyPPA
on the excitability of individual MNs
Early treatment with CyPPA does not restore passive membrane properties in SOD
MNs at symptom onset
In order to determine the long-term effects of early treatment of SOD mice with
CyPPA on the excitability of individual MNs, we first administered CyPPA to 9 SOD
mice for the same 16-day period (P5-P20) used in our initial studies. These mice or MNs
from these mice are denoted as ‘SOD-CyPPA’. Next, we aged SOD-CyPPA mice until
approximately symptom onset (95.19 days  5.05 SD, actual range: 89-104) and
examined the same intrinsic properties measured in Chapter IV. In that chapter, we
characterized the excitability of individual MNs and the spinal MN network in untreated
SOD mice at symptom onset relative to their age-matched wild-type (WT) transgenic
littermates. These SOD mice served as our official control for the current study and thus
the SOD and WT data discussed in this chapter is the same data from Chapter IV.
At symptom onset, SOD MNs exhibit both hypo- and hyperexcitable changes in
intrinsic properties relative to WT MNs. Thus, if early treatment of SOD mice with
CyPPA has long term effects on the excitability of individual SOD MNs, one or more of
these intrinsic properties would be restored in SOD-CyPPA MNs. Initially, we examined
passive membrane properties. At symptom onset, SOD MNs exhibit hypoexcitable
changes in passive membrane properties with a significant decrease in input resistance
(Rin) and a significant increase in input conductance (Gin) and capacitance compared to
WT MNs (Figure 4 and Figure 18). Following treatment with CyPPA, these deficits
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persisted. Accordingly, SOD-CyPPA MNs exhibited a significant decrease in Rin relative
to WT MNs (Figure 18A, WT 12.87 M  2.70 SD vs. SOD-CyPPA 8.68 M  1.91
SD, p = 0.00001). These values were also significantly lower than our measurements
from SOD MNs at baseline (10.75 M  3.82 SD, p = 0.026). The significant increase in
Gin (Figure 18B, WT 0.08 μS  0.02 SD vs. SOD-CyPPA 0.12 μS  0.02 SD, p =
0.00001) and capacitance (Figure 18C, WT 0.13 nF  0.04 SD vs. SOD-CyPPA 0.19 nF
 0.06 SD, p = 0.027) also continued in SOD-CyPPA MNs relative to WT MNs, but
these differences were absent between SOD-CyPPA and SOD MNs.
Similar to SOD MNs, SOD-CyPPA MNs exhibited no differences in RMP, time
constant (tau), and rheobase relative to WT MNs (Figure 18). These properties were also
similar between SOD-CyPPA and SOD MNs. Altogether, these data indicate that early
treatment of SOD mice with CyPPA does not restore passive membrane properties in
SOD MNs at symptom onset.
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Figure 18. Early treatment of SOD mice with CyPPA does not restore passive
membrane properties in SOD MNs at symptom onset
Passive membrane properties were measured in MNs from SOD mice treated with
CyPPA. Similar to SOD MNs, SOD-CyPPA MNs exhibited a significant decrease in Rin
(A) and a significant increase in Gin (B) and capacitance (C), but no differences in RMP
(D), tau (E), or rheobase (F) relative to WT MNs. Rin in SOD-CyPPA MNs was also
significantly lower compared to SOD MNs, but all other properties were similar between
these two groups. The bars represent the mean  SD. Significant differences are shown
(*, p < 0.05; **, p < 0.01, and ***, p < 0.001; Games-Howell post-hoc tests).
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Early treatment of SOD mice with CyPPA does not alter AP properties nor restore
AHP amplitude or SK channel conductance (GSK density) in SOD MNs at symptom
onset
At symptom onset, SOD MNs exhibit no alterations in AP properties (Table 2)
but show a significant reduction in AHP amplitude (Figure 6) and GSK density (Figure 7)
compared to WT MNs. Similar to SOD MNs, SOD-CyPPA MNs exhibited no changes in
AP properties relative to WT MNs (Table 6). AP properties in SOD-CyPPA MNs were
also comparable to SOD MNs. In addition, early treatment with CyPPA did not restore
AHP amplitude or GSK density in SOD MNs at symptom onset. While AHP amplitude
and GSK density in SOD-CyPPA MNs were not statistically different from WT MNs,
these properties were also similar between SOD-CyPPA and SOD MNs (Figure 19 and
Figure 20). Additionally, SOD-CyPPA MNs exhibited no differences in AHP time to
rise, half-decay, two-thirds decay, and half-duration relative to WT MNs (Table 7). These
properties were also similar between SOD-CyPPA and SOD MNs.
Early treatment of SOD mice with CyPPA does not alter repetitive firing properties
measured by long (2 s) current pulses or restore net excitability in SOD MNs at
symptom onset
At symptom onset, all repetitive firing properties measured by long current pulses
are comparable between SOD and WT MNs with the exception of the interspike interval
slope (ISI) (Table 4). Specifically, WT MNs exhibit a significant increase in ISI slope as
current pulse amplitude increases, whereas SOD MNs maintain a steady negative ISI
slope (Figure 9). A similar relationship between ISI slope and current pulse was also
found in SOD-CyPPA MNs (Figure 21). Thus, compared to WT MNs, ISI voltage in
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SOD and SOD-CyPPA MNs hyperpolarizes over time with increasing current pulse
amplitude.
Lastly, we examined repetitive firing behavior measured by triangular current
ramps. At symptom onset, despite both hypo- and hyperexcitable changes in intrinsic MN
properties, the net excitability or F-I gain7 of SOD MNs is reduced compared to WT MNs
(Figure 11). Following early treatment of SOD mice with CyPPA, these deficits were still
present (Figure 22). In addition, SOD-CyPPA MNs exhibited no differences in Ion, Ioff,
deltaI, or maximum firing frequency relative to WT MNs, which is identical to our
findings in SOD MNs at baseline (Table 8). Also, F-I gain, Ion, Ioff, deltaI, and maximum
firing frequency were comparable between SOD-CyPPA and SOD MNs.
Since ALS-induced deficits in intrinsic MN properties were not restored in SODCyPPA MNs, the data from Specific Aim 2A suggests that early treatment of SOD mice
with CyPPA does not alter individual MN excitability.

7

The ascending (F-IAsc) and descending (F-IDesc) slopes of the F-I relationship
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SOD
62.63 ± 9.70

SOD-CyPPA

AP height, mV

WT
63.03 ± 10.81

Maximum rising slope, V/s
Average rising slope, V/s
Maximum falling slope, V/s
Average falling slope, V/s
AP half-width, ms
AP width, ms
AP time to rise, ms

87.27 ± 33.08
44.60 ± 14.63
-71.91 ± 14.27
-33.97 ± 8.03
1.24 ± 0.19
3.22 ± 0.58
1.42 ± 0.30

85.98 ± 34.76
44.61 ± 16.04
-70.00 ± 16.51
-34.03 ± 9.97
1.23 ± 0.17
3.15 ± 0.61
1.45 ± 0.39

81.60 ± 35.87
39.65 ± 14.76
-69.43 ± 15.42
-32.66 ± 8.23
1.26 ± 0.17
3.26 ± 0.62
1.59 ± 0.40

60.88 ± 10.37

Table 6. AP properties in SOD-CyPPA MNs relative to WT and SOD MNs
mean  SD
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Figure 19. Early treatment of SOD mice with CyPPA does not restore AHP
amplitude in SOD MNs at symptom onset
(A) Superimposition of representative sample AHPs recorded on isolated APs from a WT
(blue), SOD (red), and SOD-CyPPA (gray) MN. At symptom onset, SOD MNs exhibit a
significant decrease in AHP amplitude relative to WT MNs (B), but this statistical
difference was absent following early treatment of SOD mice with CyPPA. However,
AHP amplitude was comparable between SOD-CyPPA and SOD MNs. Bars represent
the mean  SD. Statistical difference indicated (*, p < 0.05; Tukey’s post-hoc test).
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Figure 20. Early treatment of SOD mice with CyPPA does not restore GSK density in
SOD MNs at symptom onset
At symptom onset, SOD MNs exhibit a significant reduction in GSK density compared to
WT MNs, but this statistical difference was absent after early treatment of SOD mice
with CyPPA. However, GSK density was comparable between SOD-CyPPA and SOD
MNs. Both original (A) and transformed (B) mean values are reported, as GSK density
had a non-normal distribution. The original values were transformed using the natural
logarithm. The bars represent the mean  SD. Statistical difference indicated (*, p < 0.05;
Tukey’s post-hoc test).
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AHP amplitude, mV
AHP time to rise, ms
AHP half-decay, ms
AHP two-thirds decay, ms
AHP half-duration, ms
GSK density, S/nF
GSK density transformed

WT
2.30 ± 0.86

SOD
1.74 ± 0.75*

SOD-CyPPA

12.73 ± 4.72
19.99 ± 8.10
53.87 ± 18.01
29.92 ± 10.93
0.15  0.06
-0.86  0.19

11.89 ± 4.23
19.35 ± 9.01
59.50 ± 21.35
27.87 ± 10.62
0.11  0.13
-1.10  0.33*

11.83 ± 3.58
19.43 ± 6.44
60.84 ± 28.20
27.83 ± 6.44
0.11  0.07
-1.05  0.27

1.96 ± 1.00

Table 7. AHP properties in SOD-CyPPA MNs relative to WT and SOD MNs
mean  SD, *p < 0.05, **p < 0.01
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Figure 21. Early treatment of SOD mice with CyPPA does not alter the ISI slope
At symptom onset, SOD MNs exhibit a steady negative ISI slope with increasing current
amplitude and a similar relationship between ISI slope and current pulse was found in
SOD-CyPPA MNs. Hence, compared to WT MNs, ISI voltage in SOD and SOD-CyPPA
MNs hyperpolarizes over time with increasing current pulse amplitude. Each data point
represents the mean and error bars denote the SE. Significant differences are shown (*, p
< 0.05 and **, p < 0.01; Bonferroni multiple comparisons test) and each asterisk indicates
the difference from the first WT data point at the 1.5xR current pulse.
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Figure 22. Early treatment of SOD mice with CyPPA does not restore net
excitability in SOD MNs at symptom onset
At symptom onset, SOD MNs exhibit a significant reduction in F-IAsc compared to WT
MNs and this deficit was still present in SOD-CyPPA MNs. Similar to SOD MNs, F-IDesc
was also reduced in SOD-CyPPA MNs relative to WT MNs, but these differences were
not statistically significant. There were no differences between F-IAsc or F-IDesc between
SOD-CyPPA and SOD MNs. The bars represent the mean  SD. Statistical differences
indicated (**, p < 0.01; Tukey’s post-hoc test).
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Ion, nA
Ioff, nA
deltaI (Ioff - Ion)
Maximum firing frequency, Hz
F-IAsc, Hz/nA
F-IDesc, Hz/nA

WT
2.97 ± 1.71

SOD
4.06 ± 2.66

SOD-CyPPA

2.83 ± 1.76
0.14 ± 0.89
47.42 ± 17.44
7.96 ± 3.12
7.33 ± 3.56

3.79 ± 3.25
0.27 ± 1.15
41.77 ± 12.21
5.21 ± 2.61**
6.27 ± 2.58

4.89 ± 2.79
0.50 ± 0.93
40.31 ± 13.79
4.22 ± 2.14**
5.35 ± 1.65

5.39 ± 2.97

Table 8. Repetitive firing properties measured during triangular current ramps in
SOD-CyPPA MNs relative to WT and SOD MNs
mean  SD, **p < 0.01
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Specific Aim 2B: The long-term effects of early treatment of SOD mice with CyPPA
on the excitability of the spinal MN network
Early treatment with CyPPA does not alter sensory or descending motor inputs in the
spinal MN network of SOD mice at symptom onset
While SK channels are well-known for their regulation of the AHP, these
channels also regulate synaptic inputs, transmission, and plasticity (Faber et al., 2008;
Faber et al., 2005; Nanou et al., 2013; Ngo-Anh et al., 2005). Thus, early treatment of
SOD mice with CyPPA may alter the excitability of the spinal MN network. In Chapter
IV, we examined sensory and descending motor inputs and their integration in the spinal
MN network of SOD mice at symptom onset. To do so, we measured compound action
potentials (coAPs) produced by repetitive stimulation (5-pulse train) of sensory (via
dorsal roots) or descending motor (via remaining descending axons in the spinal cord
tissue) inputs at frequencies of 0.06 or 25 Hz and intensities of 1.5 or 10-times threshold
(1.5 or 10xT). Threshold denotes the smallest amount of current needed to evoke a coAP
and from these measurements we evaluated the amplitudes of evoked coAPs and the
degree of system short-term depression (sSTD) and facilitation (sSTF). Together, these
measurements depict the excitability of the spinal MN network. In order to determine the
long-term effects of early treatment of SOD mice with CyPPA on the excitability of the
spinal MN network, we examined these same measurements in 19 SOD-CyPPA mice
near symptom onset (99.00 days  5.20 SD, actual range: 89-109).
Similar to SOD mice, sensory and descending motor inputs in SOD-CyPPA mice
evoked comparable coAPs (Figure 23 and 24) and produced similar amounts of system
short-term plasticity (Figure 25 and 26) relative to WT mice. CoAP amplitude and
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system-short term plasticity measurements were also comparable between SOD-CyPPA
and SOD mice for both inputs. However, stimulation of descending motor inputs in SODCyPPA mice at 10-times threshold (10xT) evoked larger coAPs than at 1.5xT (Figure
24B, p < 0.001) and sSTD increased over the five pulses of sensory input stimulation at
1.5 and 10xT in these mice (Figure 25, p < 0.001). These findings were also present in
both SOD and WT mice. These data suggest that early treatment of SOD mice with
CyPPA does not influence the excitability of the spinal MN network.
Early treatment with CyPPA does not restore deficits in sensorimotor integration in
SOD mice at symptom onset
Individually, sensory and descending motor inputs trigger different patterns of
system short-term plasticity in motor output, but the integration of these two inputs
allows the production of stable and appropriate motor output for any given motor task. In
Chapter IV, we found deficits in sensorimotor integration in SOD mice at symptom
onset. Despite comparable coAPs and system-short term plasticity in SOD and WT mice
following stimulation of sensory (S) and descending motor (M) inputs separately, SOD
mice exhibited smaller coAPs in response to simultaneous stimulation (S&M) of these
inputs at 0.06 Hz irrespective of intensity, but these differences were only significant at
10xT (Figure 16). SOD mice also demonstrated significant deficits in sensorimotor
integration following 25 Hz S&M stimulation (Figure 17). These data revealed a new
mechanism contributing to the development of motor deficits in SOD mice at symptom
onset. Furthermore, early treatment of SOD mice with CyPPA may restore these deficits,
as CyPPA has been shown to sustain motor function in these mice (Dancy, 2017).
Consequently, we examined the integration of sensory and descending motor inputs in
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SOD-CyPPA mice. Similar to SOD mice, SOD-CyPPA mice exhibited smaller evoked
coAPs following S&M stimulation relative to WT mice (Figure 27). The degree of
sensorimotor integration was also significantly reduced in SOD-CyPPA mice compared
to WT mice (Figure 28). However, there were no differences in coAP amplitude and
sensorimotor integration following S&M stimulation between SOD-CyPPA and SOD
mice.
In conclusion, the data in Specific Aim 2 of this dissertation showed for the first
time the long-term effects of early treatment of SOD mice with CyPPA on the excitability
of individual MNs and the spinal MN network. In previous studies, we showed that early
treatment of SOD mice with CyPPA prolongs survival, sustains motor function, and
restores the somatic clustering profile of SK channels in SOD mice. During these studies,
treatment with CyPPA was administered for just 16 days during the neonatal period (P5P20), but the effects of this drug continued throughout disease progression. As a result,
we hypothesized that CyPPA’s impact was due to changes in the excitability of
individual MNs and/or the spinal MN network.
Nevertheless, the current study shows that early treatment of SOD mice with
CyPPA does not alter the excitability of individual MNs or the spinal MN network, as
CyPPA failed to restore ALS-induced excitability changes in individual MNs and did not
alter sensory or descending motor inputs in the spinal MN network. CyPPA also failed to
restore sensorimotor deficits in the spinal MN network of SOD mice. Therefore, it is
unlikely that the long-term therapeutic benefits of CyPPA in SOD mice are a result of
excitability changes in individual MNs or the spinal MN network.
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Figure 23. Early treatment of SOD mice with CyPPA does not alter evoked coAPs
following stimulation of sensory inputs
Repetitive stimulation (0.06 Hz at 1.5 or 10xT) of sensory inputs in SOD-CyPPA mice
evoked comparable coAPs to both SOD and WT mice. Both original (A) and transformed
(B) mean values are reported, as coAP amplitude data for sensory input stimulation had a
non-normal distribution. The original values were transformed using the natural
logarithm. The bars represent the mean  SD.
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Figure 24. Early treatment of SOD mice with CyPPA does not alter evoked coAPs
following stimulation of descending motor inputs
Repetitive stimulation (0.06 Hz at 1.5 or 10xT) of descending motor inputs in SODCyPPA mice evoked comparable coAPs to both SOD and WT mice. Additionally, much
like SOD and WT mice, stimulation of descending motor inputs in SOD-CyPPA mice at
10xT evoked significantly larger coAPs compared to 1.5xT stimulation. Both original (A)
and transformed (B) mean values are reported, as coAP amplitude data for descending
motor input stimulation had a non-normal distribution. The original values were
transformed using the natural logarithm. The bars represent the mean  SD. Statistical
differences shown (***: WT 10xT vs. 1.5xT, +++: SOD 10xT vs. 1.5xT, and •••: SODCyPPA 10xT vs. 1.5xT, p < 0.001; Bonferroni multiple comparisons test).
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Figure 25. Early treatment of SOD mice with CyPPA does not alter sSTD in sensory
inputs
At both stimulation intensities, sensory inputs in SOD-CyPPA mice exhibited
comparable amounts of sSTD to both SOD and WT mice (A and B). Additionally,
similar to SOD and WT mice, the degree of sSTD significantly increased over the five
pulses of stimulation at both 1.5 and 10xT in SOD-CyPPA mice. Bars represent mean 
SD. Statistical differences shown (***: different from WT P2 at 1.5 or 10xT, +++:
different from SOD P2 at 1.5 or 10xT, and •••: different from SOD-CyPPA P2 at 1.5 or
10xT, p < 0.001; Bonferroni multiple comparisons test).

112

1.5xT
A

10xT
B

113

Figure 26. Early treatment of SOD mice with CyPPA does not alter sSTF in
descending motor inputs
At both stimulation intensities, descending motor inputs in SOD-CyPPA mice exhibited
comparable amounts of sSTF to both SOD and WT mice (A and B). Data is represented
as mean  SD.
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Figure 27. Early treatment of SOD mice with CyPPA does not restore deficits in
evoked coAPs following S&M stimulation in SOD mice at symptom onset
Simultaneous stimulation (0.06 Hz at 1.5 or 10xT) of sensory and descending motor
inputs in SOD-CyPPA mice evoked significantly smaller coAPs at both 1.5 and 10xT
relative to WT mice, but there were no differences between SOD-CyPPA and SOD mice.
Both original (A) and transformed (B) mean values are reported, as coAP amplitude data
for simultaneous stimulation of sensory and descending motor inputs had a non-normal
distribution. The original values were transformed using the natural logarithm. The bars
represent the mean  SD. Statistical differences are shown (*, p < 0.05 and **, p < 0.01;
Bonferroni multiple comparisons test).
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Figure 28. Early treatment of SOD mice with CyPPA does not restore impairments
in the integration of sensory and descending motor inputs in SOD mice at symptom
onset
SOD-CyPPA mice exhibited a significant deficit in sensorimotor integration at both 1.5
(C) and 10xT (D) relative to WT mice. There were no differences in sensorimotor
integration between SOD-CyPPA and SOD mice. Statistical differences are indicated (*,
p < 0.05, **, p < 0.01, and ***, p < 0.001, Bonferroni multiple comparisons test).
Asterisks over the WT bars are comparing WT P1 vs. WT P2-P5 and asterisks above a
single black bar are comparing between groups).
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Chapter VI: Discussion
For the first time, the present study investigated ALS-induced excitability changes
in individual MNs at symptom onset using the standard rodent model of Amyotrophic
lateral sclerosis (ALS), SOD1-G93AHigh-Copy (SOD) mice. This study also characterized
the excitability and activity of the spinal MN network in SOD mice at symptom onset by
examining sensory and descending motor inputs and their integration. This is the first
study to examine descending motor inputs and their integration with sensory inputs in
SOD mice. In these initial studies, we sought to further understand disease versus
compensatory mechanisms in ALS, as symptom onset is the key time point in a disease,
where despite maximum compensation, disease mechanisms prevail, and signs of an
illness emerge.
The second portion of this dissertation examined the long-term effects of early
treatment of SOD mice with CyPPA on the excitability of individual MNs and the spinal
MN network. CyPPA is a small-conductance calcium-activated potassium (SK) channel
activator and in previous studies conducted in our lab, early treatment of SOD mice with
CyPPA improved their survival, prolonged their motor function, and increased the
somatic clustering profile of SK channels in their MNs. However, these studies did not
examine the effects of early treatment of SOD mice with CyPPA on the excitability of
individual MNs and the spinal MN network.
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MN Excitability in SOD Mice at Symptom Onset
Individual MN excitability
Previous studies have extensively examined individual MN excitability in SOD
mice, but these investigations are widely inconsistent and together, unclear. Throughout
the current literature, SOD MNs show hyperexcitability, hypoexcitability, or no change in
excitability depending on the study. These inconsistent findings could be the result of 1)
experimental design, such as the use of both males and females or wide age ranges, 2)
experimental error, such as the use of suboptimal discontinuous current clamp (DCC)
switching rates, which results in overestimation of MN excitability (Manuel, 2021),
and/or 3) disease and compensatory processes in ALS causing opposing changes in MN
excitability.
In the current study, we demonstrate favorable evidence of the latter in which
disease mechanisms alter MN excitability in one direction and compensatory mechanisms
pull MN excitability in the opposite direction. For the first time, we investigated changes
in MN excitability in SOD MNs at symptom onset and these MNs exhibit hypoexcitable
changes in passive membrane properties, but hyperexcitable changes in
afterhyperpolarization (AHP) properties. Also, during repetitive firing, SOD MNs
demonstrate a consistent rate of hyperpolarization in the ISI voltage. These changes could
increase sodium channel availability in SOD MNs to sustain repetitive firing. Yet, despite
evidence of both hypo- and hyperexcitable changes in different intrinsic MN properties,
the net excitability of SOD MNs at symptom onset is reduced.
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The spinal MN network
Because the firing rate of a MN is influenced by its intrinsic electrical properties
and its synaptic properties, alterations in MN excitability in ALS may develop from
changes in the synaptic inputs received by MNs. A reduction in inhibitory inputs or
increase in excitatory inputs would lead to an increase in MN firing rates, while the exact
opposite would reduce MN firing rates. In the spinal cord, three inputs regulate the firing
pattern of MNs, sensory inputs from the periphery, descending motor commands from
supraspinal structures, and local interneuronal inputs.
In the current study, we characterized sensory and descending motor inputs in the
spinal MN network of SOD mice at symptom onset. Our data demonstrates that neither
sensory nor descending motor inputs contribute to alterations in MN excitability in SOD
mice at symptom onset. Sensory and descending motor inputs from SOD and WT mice
evoked similar compound action potentials (coAPs), which suggests that these synaptic
inputs activated the same number of MNs in both SOD and WT mice. However, SOD
mice have reduced MNs prior to symptom onset (Aggarwal & Nicholson, 2002; Hegedus
et al., 2007). In addition, a previous study demonstrated a significant reduction in coAP
amplitude in sensory inputs of SOD mice starting at symptom onset (Jiang et al., 2009).
One possible explanation for the dissimilarity between the current and previous study
may be the age of mice used. While the previous study reports the age range (postnatal
day (P) 90 - P100) of mice used, the average age of these mice is unknown, which may
be misrepresentative.
In the present study, we used SOD mice ranging from P87-P99, but the average
age was P93, which is fairly close to symptom onset. Conversely, the average age of
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SOD mice from the previous study could be closer to P100 rather P90, which would put
these mice at a different clinical time point compared to the mice used in our study, as
disease processes cause rapid deterioration of SOD mice following symptom onset.
Accordingly, maximum compensatory processes at or near symptom onset may mask the
loss of MNs in SOD mice causing normal motor output or evoked coAPs and this
assumption is supported by previous studies which demonstrate that some MNs offset the
loss of neighboring MNs through sprouting (Frey et al., 2000; Mancuso et al., 2016).
At symptom onset, sensory inputs and descending motor inputs in SOD mice also
exhibit similar system short-term plasticity (depression or facilitation) relative to WT
mice. However, previous research found less system short-term depression (sSTD) in
sensory inputs of SOD mice (postnatal day (P) 50 – P90) (Jiang et al., 2017).
Dissimilarity in age range could also explain this difference relative to our results and
thus maximum compensatory processes at symptom onset may also hide these deficits.
Sensorimotor Integration in SOD Mice
Independently, sensory and descending motor inputs trigger different adaptation
patterns in motor output (Jiang et al., 2015; Mahrous et al., 2019), but together, they
produce stable and appropriate motor output for any given motor task (Kim et al., 2017;
Mahrous et al., 2019; Rossignol et al., 2006). This process is known as sensorimotor
integration and it is commonly impaired in movement disorders (Abbruzzese &
Berardelli, 2003) including Parkinson’s disease (Fellows et al., 1998; Lewis & Byblow,
2002; Rickards & Cody, 1997), Huntington’s disease (Quinn et al., 2001; Schwarz et al.,
2001), and dystonia (Ikeda et al., 1996; Serrien et al., 2000).
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Deficits in motor function are also found in ALS patients and the progressive loss and
wasting of MNs were long thought to underlie these impairments. However, recent
research suggests sensorimotor integration may contribute to the development of motor
deficits in ALS (Swash, 2018). Specifically, late somatosensory evoked potentials
(SEPs), which are involved in higher-order sensorimotor and cognitive functions, are
depressed in ALS patients (Sangari et al., 2018). Our current study also supports this new
hypothesis.
Despite normal sensory and descending motor inputs, SOD mice exhibited
significant deficits in the integration of these inputs at symptom onset. One potential
explanation for these results is spinal interneurons. There are numerous types of spinal
interneurons, each of which has different functions. Commissural interneurons, which are
well-known for their role in right-left coordination during locomotion (Butt et al., 2002;
Butt & Kiehn, 2003; Lanuza et al., 2004) also receive inputs from descending motor
tracts and relay somatosensory information to spinal neurons (Côté et al., 2018). As such,
commissural interneurons likely play a role in sensorimotor integration and could be
impaired in SOD mice at symptom onset.
Nonetheless, the role of spinal interneurons in locomotion is not fully understood
since this process involves many complex pathways and circuits. Thus, further research
must first be done to completely delineate the neural mechanisms underlying locomotor
behavior and control. Still, our study is one of several to implicate interneurons in the
pathogenesis of ALS (Do-Ha et al., 2018; Jiang et al., 2009; Martin & Chang, 2012).
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The Excitotoxicity Hypothesis in ALS
The excitotoxicity hypothesis implicates the glutaminergic system as the trigger
for MN death in ALS (King et al., 2016; Van Den Bosch et al., 2006). Put simply, this
hypothesis states that MNs in ALS are exposed to excess glutamate which causes an
increase in intracellular calcium and triggers apoptosis. Presently, this theory is widely
accepted, but it rests on several indirect findings and support from data obtained years
ago. One of the most favorable arguments in support of this theory is the fact that
Riluzole, the first and only drug shown to have a beneficial effect in ALS patients until
2017, has anti-excitotoxic properties (Bensimon et al., 1994; Lacomblez et al., 1996).
This theory has also received a lot of support from studies conducted in the 1990s which
found elevated levels of glutamate and its analogs in the cerebrospinal fluid (CSF) of
ALS patients (Rothstein et al., 1990) and deficits in glutamate transport in the spinal cord
and brain of ALS patients (Rothstein et al., 1992; Rothstein et al., 1995). Still, if the
excitotoxicity hypothesis holds true, MNs in ALS would be hyperexcitable.
To date, numerous studies have investigated MN excitability in ALS using SOD
mice. Many of these studies found hyperexcitability (Jensen et al., 2020; Kuo et al., 2004;
Kuo et al., 2005; Martin et al., 2013) in SOD MNs which supports the excitotoxicity
hypothesis, but others contradicted this hypothesis with evidence of hypoexcitability or
no change in excitability in SOD MNs (Delestrée et al., 2014; Leroy et al., 2014;
Martínez-Silva et al., 2018). The results of the current study help to explain this
disagreement within current ALS literature. At symptom onset, SOD MNs exhibit both
hypo- and hyperexcitability changes in intrinsic MN properties. This data supports

124

evidence of both hypo- and hyperexcitability in MNs in ALS, in which one is a disease
mechanism and the other is a compensatory mechanism.
Nevertheless, despite both hypo- and hyperexcitable changes in SOD MNs at
symptom onset, the net excitability of these cells is reduced. Because symptom onset is
the unique time point of a disease where despite maximum compensation, disease
mechanisms predominate, these results suggest hypoexcitability as the disease
mechanism in ALS. Accordingly, our results do not support the excitotoxicity theory, but
previous research demonstrates that reducing MN excitability in SOD mice accelerates
disease, while enhancing MN excitability promotes neuroprotection (Saxena et al., 2013).
MN hypoexcitability also predominates in sporadic ALS patients and increases with
disease progression (Marchand-Pauvert et al., 2019). Still, additional research must be
conducted in order to confirm hypoexcitability reflects disease processes in ALS.
Additionally, some limitations from our study should also be noted. Compared to a recent
study conducted by Jensen and colleagues (2020), which found MNs from
presymptomatic (P69-P75) and symptomatic (P107-P116) SOD mice to be more
responsive or hyperexcitable, the sample size in our study was small. Nevertheless, our
post-hoc power values are within appropriate limits (see the Appendix) and unlike the
study conducted in 2020, our results are supported by immunohistochemistry and
computer modeling studies and we used appropriate discontinuous current clamp (DCC)
sampling rates. Also, the MNs we recorded from in the current study were mostly (83%)
fast or F-type MNs according to AHP half decay measurements (Table 7). Consequently,
our results reflect the excitability state of the most vulnerable MNs in ALS at symptom
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onset, but do not represent the excitability state of slow or S-type MNs, the disease
resistant MNs in ALS.
CyPPA Treatment in SOD mice
The effects of early treatment of SOD mice with CyPPA
Due to the limited therapeutic options for ALS, our lab began investigating a new
molecule potentially involved in ALS disease pathogenesis, the SK channel. Collectively,
our past studies demonstrate a significant reduction in SK channels in SOD mice
throughout disease progression (Dukkipati, 2016). Following treatment with CyPPA, an
SK channel activator, for a single, 16-day period (P5-P20), these deficits are restored
immediately (P21) and last long-term (symptom onset or P90) (Murphy, 2020). CyPPA
also sustains motor function and prolongs survival in SOD mice by 10 days (Dancy,
2017).
The longstanding effects of early treatment of SOD mice with CyPPA suggest
that CyPPA has functional effects on MNs and likely alters their excitability at the
individual and/or network levels. Since CyPPA is an SK channel activator, we
hypothesized that CyPPA alters AHP properties and/or synaptic properties in SOD MNs.
In the current study, we tested this hypothesis and surprisingly, early treatment with
CyPPA failed to restore deficits in AHP properties and all other intrinsic MN properties,
including passive membrane properties and net excitability, in SOD MNs at symptom
onset.
In addition, CyPPA did not alter sensory or descending motor inputs nor restore
deficits in the integration of these inputs in SOD mice at symptom onset. Altogether,
these data suggest CyPPA’s long-term therapeutic effects in SOD mice are not related to
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alterations in MN excitability at the individual or network levels. However, these results
contradict the previous immunohistochemistry studies conducted in our lab which found
CyPPA to restore the somatic clustering profile of SK channels in SOD mice at symptom
onset. This could be due to the small and unbalanced sample sizes used in the current
study or because changes in ion channel cluster size do not equate to changes in ion
channel conductance.
Possible mechanisms underlying the therapeutic benefit of CyPPA in SOD mice
Despite the extensive focus on the glutamate excitotoxicity hypothesis in ALS,
several other hypotheses have been proposed as mechanisms contributing to MN
degeneration in this disease (R. Bonafede & R. Mariotti, 2017). Two examples of these
mechanisms are mitochondrial dysfunction and neuroinflammation, both of which are
modified by SK channel activation (Dolga et al., 2012; Gold, 2013; Honrath et al., 2018;
Richter et al., 2015). More recently SK channels have been shown to be expressed and
functional at the level of the mitochondrial membrane (Dolga et al., 2013; Stowe et al.,
2013) and activation of these channels via CyPPA reduces mitochondrial respiration,
oxygen consumption, and ROS production (Richter et al., 2015). Therefore, early
treatment of SOD mice with CyPPA could target mitochondrial dysfunction and
oxidative stress-related mechanisms in ALS.
SK channels are also linked to microglia activation processes (Khanna et al.,
2001; Schlichter et al., 2010) and these cells are the first line of defense for the CNS
against infection or injury, and accordingly, these cells initiate neuroinflammation
(Roberta Bonafede & Raffaella Mariotti, 2017; Carroll & Chesebro, 2019; RodríguezGómez et al., 2020). Activation of SK channels by CyPPA reduces lipopolysaccharide-
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induced microglia activation via attenuation of calcium influx and decreases cytokine
production, a characteristic feature of microglia activation (Dolga et al., 2012). Thus,
CyPPA could also target microglia activity in SOD mice. Remarkably, studies in these
transgenic mice have shown that replacement of mutant microglia with normal cells
significantly reduces MN degeneration and extends the lifespan of these animals (Beers
et al., 2006; Boillée et al., 2006). SK channel activation via CyPPA also protects against
cell death induced by ER-stress, another pathogenic mechanism proposed in ALS
(Richter et al., 2016). Taken together, CyPPA could impact various disease processes
involved in ALS. Consequently, additional research must be conducted in order to
delineate the exact mechanism underlying the long-term therapeutic benefits of CyPPA in
SOD mice.
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Chapter VII: Appendix
Analysis

Test

Test value
15.982

P-value
0.00001

Power
0.954

One-way ANOVA

18.081
7.971
3.151
4.173

0.000002
0.001
0.049
0.020

0.962
0.770
0.587
0.714

2.880
8.854

0.0332
0.0004

0.734
0.965

68.616

< 0.001

1.000

Two-way Mixed ANOVA
(Pulse)
Two-way Mixed ANOVA
(Pulse)
Two-way ANOVA

209.588

< 0.001

1.000

186.727

< 0.001

1.000

10.465

< 0.001

0.986

Two-way Mixed ANOVA
(Genotype)

3.918

0.028

0.673

Two-way Mixed ANOVA
(Pulse)

15.478

< 0.001

0.997

Two-way Mixed ANOVA
(Genotype)

5.476

0.008

0.822

Two-way Mixed ANOVA
(Pulse)

17.504

< 0.001

1.000

Rin
Gin
Capacitance
AHP amplitude
GSK density

Two-way Mixed ANOVA
ISI slope
One-way ANOVA
F-IAsc
Descending
Motor Input
coAP amplitude
sSTD 1.5xT
sSTD 10xT
S&M coAP
amplitude
Sensorimotor
Integration
1.5xT
Sensorimotor
Integration
1.5xT
Sensorimotor
Integration 10xT
Sensorimotor
Integration 10xT

Two-way ANOVA (Intensity)
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